Renal denervation balloon catheter with ride along electrode support

Description

TECHNICAL FIELD

The present disclosure pertains to medical devices, and methods for using and manufacturing medical devices. More particularly, the present disclosure pertains to medical devices for renal nerve ablation.

BACKGROUND

A wide variety of intracorporal medical devices have been developed for medical use, for example, intravascular use. Some of these devices include guidewires, catheters, and the like. These devices are manufactured by any one of a variety of different manufacturing methods and may be used according to any one of a variety of methods. Of the known medical devices and methods, each has certain advantages and disadvantages. There is an ongoing need to provide alternative medical devices as well as alternative methods for manufacturing and using medical devices.

BRIEF SUMMARY

A medical device for renal nerve ablation may include a catheter shaft, an expandable member coupled to the catheter shaft, the expandable member having a proximal region, a distal region, and a body extending therebetween. The medical device may further include an electrode support coupled to the catheter shaft and positioned over the body of the expandable member, the electrode support including a plurality of flexible elongate members and a plurality of electrode assemblies disposed on the elongate members, the electrode support capable of expanding with the expandable member, wherein the electrode support is free from attachment with the body of the expandable member.

A medical device may include a catheter shaft, an expandable balloon, a flexible elongate electrode assembly, and a plurality of electrode elements. The expandable balloon may have a distal waist, proximal waist, and a body extending therebetween, the proximal waist being coupled to the catheter shaft. The flexible elongate electrode assembly may be coupled to the catheter shaft and may extend in a helix over the body of the expandable balloon, the electrode assembly free from attachment to the body of the expandable balloon. The plurality of electrode elements may be disposed on the flexible elongate electrode assembly.

A method for treating hypertension may include providing a medical device, the medical device including a catheter shaft, an expandable member coupled to the catheter shaft, an expandable electrode support coupled to the catheter shaft and positioned over the expandable member, the electrode support including a plurality of flexible elongate members and a plurality of electrode assemblies disposed on the elongate members, the electrode support capable of expanding with the expandable member, wherein the electrode support is free from attachment with the expandable member, and a delivery sheath. The method may further include the steps of advancing the medical device through a blood vessel to a position within a renal artery, expanding the expandable member, thereby expanding the electrode support, energizing the electrode assemblies, collapsing the expandable member, and thereafter, withdrawing the expandable member and the electrode support into the delivery sheath, thereby collapsing the electrode support.

The above summary of some embodiments is not intended to describe each disclosed embodiment or every implementation of the present disclosure. The Figures, and Detailed Description, which follow, more particularly exemplify these embodiments.

BRIEF DESCRIPTION OF THE DRAWINGS

The disclosure may be more completely understood in consideration of the following detailed description in connection with the accompanying drawings, in which:

FIG. 1 is a schematic view of an example renal nerve ablation device;

FIG. 2 is a perspective view of an example expandable member of a renal nerve ablation device;

FIG. 3 is a partial top view of the expandable member of FIG. 2 in an unrolled or flat configuration;

FIG. 4 is a top view of a portion of an example electrode assembly;

FIG. 5 is a partial cross-sectional view A-A of FIG. 4;

FIG. 6 is a partial cross-sectional view B-B of FIG. 4;

FIG. 7 is a perspective view of an example renal nerve ablation device;

FIG. 8 is a perspective view of the electrode support of FIG. 7;

FIG. 9 is a perspective view of an example expandable member;

FIG. 10 is an end view of the expandable member of FIG. 9;

FIG. 11 is a perspective view of the expandable member of FIG. 9 with an electrode support;

FIG. 12 is a perspective view of another example renal nerve ablation device;

FIG. 13 is a partial top view of the electrode support of FIG. 12 in an unrolled or flat configuration;

FIG. 14 is a perspective view of another example renal nerve ablation device; and

FIG. 15 is a perspective view of another example renal nerve ablation device.

While the disclosure is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.

DETAILED DESCRIPTION

The following description should be read with reference to the drawings, which are not necessarily to scale, wherein like reference numerals indicate like elements throughout the several views. The detailed description and drawings are intended to illustrate but not limit the claimed invention. Those skilled in the art will recognize that the various elements described and/or shown may be arranged in various combinations and configurations without departing from the scope of the disclosure. The detailed description and drawings illustrate example embodiments of the claimed invention.

For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.

All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about”, in the context of numeric values, generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same function or result). In many instances, the term “about” may include numbers that are rounded to the nearest significant figure. Other uses of the term “about” (i.e., in a context other than numeric values) may be assumed to have their ordinary and customary definition(s), as understood from and consistent with the context of the specification, unless otherwise specified.

The recitation of numerical ranges by endpoints includes all numbers within that range, including the endpoints (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).

As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.

It is noted that references in the specification to “an embodiment”, “some embodiments”, “other embodiments”, etc., indicate that the embodiment(s) described may include a particular feature, structure, or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it would be within the knowledge of one skilled in the art to effect such feature, structure, or characteristic in connection with other embodiments, whether or not explicitly described, unless clearly stated to the contrary. That is, the various individual elements described below, even if not explicitly shown in a particular combination, are nevertheless contemplated as being combined or arranged with each other to form other additional embodiments or to complement and/or enrich the described embodiment(s), as would be understood by one of ordinary skill in the art.

Certain treatments are aimed at the temporary or permanent interruption or modification of select nerve function. One example treatment is renal nerve ablation, which is sometimes used to treat conditions such as or related to hypertension, congestive heart failure, diabetes, or other conditions impacted by high blood pressure or salt retention. The kidneys produce a sympathetic response, which may increase the undesired retention of water and/or sodium. The result of the sympathetic response, for example, may be an increase in blood pressure. Ablating some of the nerves running to the kidneys (e.g., disposed adjacent to or otherwise along the renal arteries) may reduce or eliminate this sympathetic response, which may provide a corresponding reduction in the associated undesired symptoms (e.g., a reduction in blood pressure).

Some embodiments of the present disclosure relate to a power generating and control apparatus, often for the treatment of targeted tissue in order to achieve a therapeutic effect. In some embodiments, the target tissue is tissue containing or proximate to nerves, including renal arteries and associated renal nerves. In other embodiments the target tissue is luminal tissue, which may further comprise diseased tissue such as that found in arterial disease.

In some embodiments of the present disclosure, the ability to deliver energy in a targeted dosage may be used for nerve tissue in order to achieve beneficial biologic responses. For example, chronic pain, urologic dysfunction, hypertension, and a wide variety of other persistent conditions are known to be affected through the operation of nervous tissue. For example, it is known that chronic hypertension that may not be responsive to medication may be improved or eliminated by disabling excessive nerve activity proximate to the renal arteries. It is also known that nervous tissue does not naturally possess regenerative characteristics. Therefore it may be possible to beneficially affect excessive nerve activity by disrupting the conductive pathway of the nervous tissue. When disrupting nerve conductive pathways, it is particularly advantageous to avoid damage to neighboring nerves or organ tissue. The ability to direct and control energy dosage is well-suited to the treatment of nerve tissue. Whether in a heating or ablating energy dosage, the precise control of energy delivery as described and disclosed herein may be directed to the nerve tissue. Moreover, directed application of energy may suffice to target a nerve without the need to be in exact contact, as would be required when using a typical ablation probe. For example, eccentric heating may be applied at a temperature high enough to denature nerve tissue without causing ablation and without requiring the piercing of luminal tissue. However, it may also be desirable to configure the energy delivery surface of the present disclosure to pierce tissue and deliver ablating energy similar to an ablation probe with the exact energy dosage being controlled by a power control and generation apparatus.

In some embodiments, efficacy of the denervation treatment can be assessed by measurement before, during, and/or after the treatment to tailor one or more parameters of the treatment to the particular patient or to identify the need for additional treatments. For instance, a denervation system may include functionality for assessing whether a treatment has caused or is causing a reduction in neural activity in a target or proximate tissue, which may provide feedback for adjusting parameters of the treatment or indicate the necessity for additional treatments.

While the devices and methods described herein are discussed relative to renal nerve ablation and/or modulation, it is contemplated that the devices and methods may be used in other treatment locations and/or applications where nerve modulation and/or other tissue modulation including heating, activation, blocking, disrupting, or ablation are desired, such as, but not limited to: blood vessels, urinary vessels, or in other tissues via trocar and cannula access. For example, the devices and methods described herein can be applied to hyperplastic tissue ablation, cardiac ablation, pulmonary vein isolation, pulmonary vein ablation, tumor ablation, benign prostatic hyperplasia therapy, nerve excitation or blocking or ablation, modulation of muscle activity, hyperthermia or other warming of tissues, etc.

FIG. 1 is a schematic view of an example renal nerve ablation system 100. System 100 may include a renal nerve ablation device 120. Renal nerve ablation device 120 may be used to ablate nerves (e.g., renal nerves) disposed adjacent to the kidney K (e.g., renal nerves disposed about a renal artery RA). In use, renal nerve ablation device 120 may be advanced through a blood vessel such as the aorta A to a position within the renal artery RA. This may include advancing renal nerve ablation device 120 through a guide sheath or catheter 14. When positioned as desired, renal nerve ablation device 120 may be activated to activate one or more electrodes (not shown). This may include operatively coupling renal nerve ablation device 120 to a control unit 110, which may include an RF generator, so as to supply the desired activation energy to the electrodes. For example, renal nerve ablation device 120 may include a wire or conductive member 18 with a connector 20 that can be connected to a connector 22 on the control unit 110 and/or a wire 24 coupled to the control unit 110. In at least some embodiments, the control unit 110 may also be utilized to supply/receive the appropriate electrical energy and/or signal to activate one or more sensors disposed at or near a distal end of renal nerve ablation device 120. When suitably activated, the electrodes may be capable of ablating tissue (e.g., renal nerves) as described below and the sensors may be used to detect desired physical and/or biological parameters.

An exemplary control unit 110 and associated energy delivery methods useable with the embodiments disclosed herein are disclosed in U.S. Patent Application Publication No. 2012/0095461 entitled “Power Generating and Control Apparatus for the Treatment of Tissue”, the full disclosure of which is incorporated by reference herein. Further examples useable with the embodiments disclosed herein are disclosed in U.S. Pat. No. 7,742,795 entitled “Tuned RF Energy for Selective Treatment of Atheroma and Other Target Tissues and/or Structures”, U.S. Pat. No. 7,291,146 entitled “Selectable Eccentric Remodeling and/or Ablation of Atherosclerotic Material”, and U.S. Patent Application Publication No. 2008/0188912 entitled “System for Inducing Desirable Temperature Effects on Body Tissue”, the full disclosures of which are incorporated herein by reference. In some embodiments, particularly in some embodiments utilizing monopolar energy delivery, the system 100 may also include a ground/common electrode (not shown), which may be associated with the ablation device 120. The ground/common electrode may be a separate pad that is electrically or otherwise operatively coupled to the control unit 110, or otherwise associated with the system 100.

In some embodiments, the control unit 110 may include a processor or otherwise be coupled to a processor to control or record treatment. The processor may typically comprise computer hardware and/or software, often including one or more programmable processor units running machine-readable program instructions or code for implementing some, or all, of one or more of the embodiments and methods described herein. The code may often be embodied in a tangible media such as a memory (optionally a read-only memory, a random access memory, a non-volatile memory, or the like) and/or a recording media (such as a floppy disk, a hard drive, a CD, a DVD, or other optical media, a non-volatile solid-state memory card, or the like). The code and/or associated data and signals may also be transmitted to or from the processor via a network connection (such as a wireless network, an ethernet, an internet, an intranet, or the like), and some or all of the code may also be transmitted between components of a renal nerve ablation system and within the processor via one or more buses, and appropriate standard or proprietary communications cards, connectors, cables, and the like may often be included in the processor. The processor may often be configured to perform the calculations and signal transmission steps described herein at least in part by programming the processor with the software code, which may be written as a single program, a series of separate subroutines or related programs, or the like. The processor may comprise standard or proprietary digital and/or analog signal processing hardware, software, and/or firmware, and may desirably have sufficient processing power to perform the calculations described herein during treatment of the patient, the processor may optionally comprise a personal computer, a notebook computer, a tablet computer, a proprietary processing unit, or a combination thereof. Standard or proprietary input devices (such as a mouse, keyboard, touchscreen, joystick, etc.) and output devices (such as a printer, speakers, display, etc.) associated with modern computer systems may also be included, and processors having a plurality of processing units (or even separate computers) may be employed in a wide range of centralized or distributed data processing architectures.

In some embodiments, control software for the system 100 may use a client-server scheme to further enhance system ease of use, flexibility, and reliability. “Clients” may be the system control logic; “servers” may be the control hardware. A communications manager may deliver changes in system conditions to subscribing clients and servers. Clients may “know” what the present system condition is, and what command or decision to perform based on a specific change in condition. Servers may perform the system function based on client commands. Because the communications manager may be a centralized information manager, new system hardware may not require changes to prior existing client-server relationships; new system hardware and its related control logic may then merely become an additional “subscriber” to information managed through the communications manager. This control schema may provide the benefit of having a robust central operating program with base routines that are fixed; no change to base routines may be necessary in order to operate new circuit components designed to operate with the system.

In some embodiments, the renal nerve ablation device 120 may include an elongate tubular member or catheter shaft 122, as shown in FIG. 2. In some embodiments, the elongate tubular member or catheter shaft 122 may be configured to be slidingly advanced over a guidewire or other elongate medical device to a target site. In some embodiments, the elongate tubular member or catheter shaft 122 may be configured to be slidingly advanced within a guide sheath or catheter 14 to a target site. In some embodiments, the elongate tubular member or catheter shaft 122 may be configured to be advanced to a target site over a guidewire, within a guide sheath or catheter 14, or a combination thereof.

An expandable member 130 may be disposed at, on, about, or near a distal region of the elongate tubular member or catheter shaft 122. The expandable member 130 may have a body 135, a proximal waist 136, and a distal waist 137. In some embodiments, the expandable member 130 may be fixedly attached to the elongate tubular member or catheter shaft 122. In some embodiments the proximal waist 136 and the distal waist 137 are attached to the catheter shaft 122 while the body 135 is free from attachment to the catheter shaft 122. In some embodiments, the expandable member 130 may be self-expanding from a collapsed delivery state to an expanded state, such as a basket, a swellable foam or other material, or a plurality of struts, for example. In some embodiments, the expandable member 130 may be selectively expanded from a collapsed delivery state to an expanded state, such as a compliant, non-compliant, or semi-compliant balloon, for example. In some embodiments, one or more electrodes may be disposed on, disposed about, or coupled to an outer surface of the expandable member 130. In some embodiments, the one or more electrodes may be operatively and/or electrically connected to the control unit 110 and/or the RF generator. In some embodiments, the one or more electrodes may include a plurality of electrode assemblies. In some embodiments, one or more of the plurality of electrode assemblies may be configured to be monopolar or bipolar, and may further include a temperature sensor, for example, a thermistor or thermocouple.

For example, as shown in FIG. 2, in some embodiments, the electrode assemblies may be arranged on the expandable member 130, shown here in an expanded state, according to a plurality of generally cylindrical treatment zones A-D. In other embodiments, the expandable member 130 or other components of the treatment system may include additional electrode assemblies that are not in a treatment zone or are otherwise not used or configured to deliver a treatment energy.

The treatment zones A-D and associated electrode assemblies 140a-d are further illustrated in FIG. 3, which is an “unrolled” depiction of a portion of the expandable member 130 of FIG. 2. In some embodiments, the expandable member may be a balloon with a 4 mm diameter and two electrode assemblies 140a-b. In other embodiments, the expandable member may be a balloon with a 5 mm diameter and three electrode assemblies 140a-c. In some embodiments, the expandable member may be a balloon with a 6, 7, or 8 mm diameter and four electrode assemblies 140a-d, as depicted in FIG. 2. For any of these configurations, the expandable member may have a working length of about 10 mm to about 100 mm, or about 18 mm to about 25 mm, which may be the approximate longitudinal span of all the treatment zones A-D shown in FIGS. 2 and 3. The electrode assemblies 140a-d may be attached to a balloon using adhesive, or other suitable means.

Returning to FIG. 2, the treatment zones A-D may be longitudinally adjacent to one another along longitudinal axis L-L, and may be configured such that energy applied by the electrode assemblies create treatments that do not overlap. Treatments applied by the longitudinally adjacent bipolar electrode assemblies 140a-d may be circumferentially non-continuous along longitudinal axis L-L. For example, with reference to FIG. 3, lesions created in treatment zone A may in some embodiments minimize overlap about a circumference (laterally with respect to L-L in this view) with lesions created in treatment zone B. In other embodiments, however, the energy applied by the electrode assemblies, such as the electrode assemblies shown in FIG. 3, may overlap, longitudinally, circumferentially, and/or in other ways, to at least some extent.

Whether or not treatment zones between electrodes/electrode pairs will overlap may be influenced by a wide variety of factors, including, but not limited to, electrode geometry, electrode placement density, electrode positioning, ground/common electrode(s) placement and geometry (in monopolar embodiments), energy generator output settings, output voltage, output power, duty cycle, output frequency, tissue characteristics, tissue type, etc. In some embodiments, individual electrodes of a bipolar electrode pair may each define its own treatment zone, and such treatment zones may partially or entirely overlap. In some embodiments, the overlap of treatment zones may extend substantially continuously around a circumference of the expandable member and/or around a circumference in a tissue surrounding a body passageway. In other embodiments, there may be overlap in treatment zones, however, that overlap may not be substantially continuous around a circumference and significant discontinuities in the treatment zones may be present.

Returning to FIG. 3, each electrode pad assembly may include four major elements, which are a distal electrode pad 150a-d, intermediate tail 160a-d, proximal electrode pad 170a-d, and proximal tail 180b,d (not shown for electrode pad assemblies 140b and 140c). Constructional details of the electrode assemblies 140a-d are shown and described with reference to FIGS. 4-6.

FIG. 4 shows a top view of electrode assembly 200, which is identified in FIG. 3 as electrode assembly 140. The electrode assembly 200 may be constructed as a flexible circuit having a plurality of layers. Such layers may be continuous or non-contiguous, i.e., made up of discrete portions. Shown in FIGS. 5 and 6, a base layer 202 of insulation may provide a foundation for the electrode assembly 200. The base layer 202 may be constructed from a flexible polymer such as polyimide, although other materials are contemplated. In some embodiments, the base layer 202 may be from about 0.01 mm thick to about 0.02 mm thick. In some embodiments, the base layer 202 may be approximately 0.5 mil (0.0127 mm) thick. A conductive layer 204 made up of a plurality of discrete traces may be layered on top of the base layer 202. The conductive layer 204 may be, for example, a layer of electrodeposited copper. Other materials are also contemplated. In some embodiments, the conductive layer 204 may be from about 0.01 mm thick to about 0.02 mm thick. In some embodiments, the conductive layer 204 may be approximately 0.5 mil (0.018 mm) thick. An insulating layer 206 may be discretely or continuously layered on top of the conductive layer 204, such that the conductive layer 204 may be fluidly sealed between the base layer 202 and the insulating layer 206. Like the base layer 202, the insulating layer 206 may be constructed from a flexible polymer such as polyimide, although other materials are contemplated. In some embodiments, the insulating layer 206 may be from about 0.01 mm thick to about 0.02 mm thick. In some embodiments, the insulating layer 206 may be approximately 0.5 mil (0.0127 mm) thick. In other embodiments, the insulating layer 206 may be a complete or partial polymer coating, such as PTFE or silicone. Other materials are also contemplated.

The electrode assembly 200 shown in FIG. 4 may include a distal electrode pad 208. In this region, the base layer 202 may form a rectangular shape. This is not intended to be limiting. Other shapes are contemplated. As shown, the electrode assembly 200 may include a plurality of openings to provide for added flexibility, and the pads and other portions of the assemblies may include rounded or curved corners, transitions and other portions. In some instances, the openings and rounded/curved features may enhance the assembly's resistance to delamination from its expandable device, as may occur, in some instances, when the expandable device is repeatedly expanded and collapsed (which may also entail deployment from and withdrawal into a protective sheath), such as may be needed when multiple sites are treated during a procedure.

The distal electrode pad 208 may include a plurality of discrete traces layered on top of the base layer 202. These traces may include a ground trace 210, an active electrode trace 212, and a sensor trace 214. The ground trace 210 may include an elongated electrode support 216 laterally offset from a sensor ground pad 218. The sensor ground pad 218 may be electrically coupled to the elongated electrode support 216 of the ground trace 210 and may be centrally located on the distal electrode pad 208. A bridge 220 may connect a distal most portion of the sensor ground pad 218 to a distal portion of the elongated electrode support 216 of the ground trace 210. The bridge 220 may taper down in width as it travels to the sensor ground pad 218. In some embodiments, the bridge 220 may have a relatively uniform and thin width to enable a desired amount of flexibility. The elongated electrode support 216 may taper down in width at its proximal end, however, this is not required. In some embodiments, the elongated electrode support 216 may abruptly transition to a much thinner trace at its proximal portion, to enable a desired amount of flexibility. Generally, the curvature of the traces where necking is shown may be optimized to reduce balloon recapture forces and the potential for any snagging that sharper contours may present. The shape and position of the traces may also be optimized to provide dimensional stability to the electrode assembly 200 as a whole, so as to prevent distortion during deployment and use.

The ground trace 210 and active electrode trace 212 of FIG. 4 may share a similar construction. The active electrode trace 212 may also include an elongated electrode support 216.

FIG. 5 shows a partial cross-section A-A of the distal electrode pad 208. An electrode 222 is shown layered over a portion of the insulating layer 206, which may have a plurality of passages (e.g., holes) to enable the electrode 222 to couple to the elongated electrode support 216 of the ground trace 210 (of conductive layer 204).

As shown in FIG. 4, the ground electrode trace 210 and active electrode trace 212 may include a plurality of electrodes. Three electrodes 222 may be provided for each electrode trace, however, more or less may be used. Additionally, each electrode 222 may have radiused corners to reduce tendency to snag on other devices and/or tissue. Although the above description of the electrodes 222 and the traces associated with them has been described in the context of a bi-polar electrode assembly, those of skill in the art will recognize that the same electrode assembly may function in a monopolar mode as well. For instance, as one non-limiting example, the electrodes associated with active electrode traces 212 and 242 may be used as monopolar electrodes, with ground trace 210 disconnected during energization of those electrodes.

In some embodiments, as shown in FIG. 4 for example, each electrode 222 may be approximately 1.14 mm by 0.38 mm, with approximately 0.31 mm gaps lying between the electrodes 222. The electrodes 222 of the ground trace 210 and active electrode trace 212 may be laterally spaced by approximately 1.85 mm. In some embodiments, as shown in FIG. 5 for example, the electrodes 222 may be gold pads approximately 0.038 mm thick from the conductive layer 204 and that may protrude about 0.025 mm above the insulating layer 206. Without limiting the use of other such suitable materials, gold may be a good electrode material because it is very biocompatible, radiopaque, and electrically and thermally conductive. In other embodiments, the electrode thickness of the conductive layer 204 may range from about 0.030 mm to about 0.051 mm. At such thicknesses, relative stiffness of the electrodes 222, as compared to, for example, the copper conductive layer 204, may be high. Because of this, using a plurality of electrodes, as opposed to a single electrode, may increase flexibility. In other embodiments, the electrodes may be as small as about 0.5 mm by about 0.2 mm or as large as about 2.2 mm by about 0.6 mm for electrode 222.

While it may be an important design optimization consideration to balance the thickness of the gold above the insulating layer 206 so as to achieve good flexibility while maintaining sufficient height so as to provide good tissue contact, this may be counterbalanced with the goal of avoiding a surface height that may snag during deployment or collapse of the balloon. These issues may vary according to other elements of a particular procedure, such as balloon pressure. For many embodiments, it has been determined that electrodes that protrude approximately 0.025 mm above the insulating layer 206 will have good tissue contact at balloon inflation pressures below 10 atm and as low as 2 atm. These pressures may be well below the typical inflation pressure of an angioplasty balloon.

The sensor trace 214 may be centrally located on the distal electrode pad 208 and may include a sensor power pad 224 facing the sensor ground pad 218. These pads may connect to power and ground poles of a temperature sensor 226, such as a thermocouple (for example, Type T configuration: Copper/Constantan) or thermistor, as shown in the partial cross-section depicted in FIG. 6.

The temperature sensor 226 may be proximately connected to the sensor power pad 224 and may be distally connected to the sensor ground pad 218. To help reduce overall thickness, the temperature sensor 226 may be positioned within an opening within the base layer 202. In some embodiments, the temperature sensor 226 may be a thermistor having a thickness of about 0.1 mm, which is unusually thin—approximately two-thirds of industry standard. As shown, the temperature sensor 226 may be on a non-tissue contacting side of the distal electrode pad 208. Accordingly, the temperature sensor 226 may be captured between the electrode structure and a balloon when incorporated into a final device, such as ablation device 120. This may be advantageous since surface-mounted electrical components, like thermistors, typically have sharp edges and corners, which may get caught on tissue and possibly cause problems in balloon deployment and/or retraction. This arrangement may also keep soldered connections from making contact with blood, since solder is typically non-biocompatible. Further, due to the placement of the temperature sensor, it may measure temperature representative of tissue and the electrodes 222.

From the distal electrode pad 208, the combined base layer 202, conductive layer 204, and insulating layer 206 may reduce in lateral width to an intermediate tail 228. Here, the conductive layer 204 may be formed to include an intermediate ground line 230, intermediate active electrode line 232, and intermediate sensor line 234, which may be respectively coextensive traces of the ground trace 210, active electrode trace 212, and sensor trace 214 of the distal electrode pad 208.

From the intermediate tail 228, the combined base layer 202, conductive layer 204, and insulating layer 206 may increase in lateral width to form a proximal electrode pad 236. The proximal electrode pad 236 may be constructed similarly to the distal electrode pad 208, with the electrode geometry and temperature sensor arrangement being essentially identical, although various differences may be present. However, as shown, the proximal electrode pad 236 may be laterally offset from the distal electrode pad 208 with respect to a central axis G-G extending along the intermediate ground line 230. The intermediate active electrode line 232 and intermediate sensor line 234 may be laterally coextensive with the proximal electrode pad 236 on parallel respective axes with respect to central axis G-G.

From the proximal electrode pad 236, the combined base layer 202, conductive layer 204, and insulating layer 206 may reduce in lateral width to form a proximal tail 238. The proximal tail 238 may include a proximal ground line 240, proximal active electrode line 242, and proximal sensor line 244, as well the intermediate active electrode line 232 and intermediate sensor line 234. The proximal tail 238 may include connectors (not shown) to enable coupling to one or more sub-wiring harnesses and/or connectors and ultimately to control unit 110. Each of these lines may be extended along parallel respective axes with respect to central axis G-G.

As shown, the electrode assembly 200 may have an asymmetric arrangement of the distal electrode pad 208 and proximal electrode pad 236, about axis G-G. Further, the ground electrodes of both electrode pads may be substantially aligned along axis G-G, along with the intermediate and proximal ground lines 230/240. It has been found that this arrangement may present certain advantages. For example, by essentially sharing the same ground trace, the width of the proximal tail may be only about one and a half times that of the intermediate tail 228, rather than being approximately twice as wide if each electrode pad had independent ground lines. Thus, the proximal tail 238 may be narrower than two of the intermediate tails 228.

Further, arranging the electrode pads to share a ground trace may allow control of which electrodes will interact with each other. This may not be immediately apparent when viewing a single electrode assembly, but may become evident when more than one electrode assembly 200 is assembled onto an expandable member, such as a balloon, for example as shown in FIG. 3. The various electrode pads may be fired and controlled using solid state relays and multiplexing with a firing time ranging from about 100 microseconds to about 200 milliseconds or about 10 milliseconds to about 50 milliseconds. For practical purposes, the electrode pads may appear to be simultaneously firing yet stray current between adjacent electrode pads of different electrode assemblies 200 may be prevented by rapid firing of electrodes in micro bursts. This may be performed such that adjacent electrode pads of different electrode pad assemblies 200 are fired out of phase with one another. Thus, the electrode pad arrangement of the electrode assembly may allow for short treatment times—about 10 minutes or less of total electrode firing time, with some approximate treatment times being as short as about 10 seconds, with an exemplary embodiment being about 30 seconds. Some benefits of short treatment times may include minimization of post-operative pain caused when nerve tissue is subject to energy treatment, shortened vessel occlusion times, reduced occlusion side effects, and quick cooling of collateral tissues by blood perfusion due to relatively minor heat input to luminal tissue.

In some embodiments, the common ground may typically carry 200 VAC at 500 kHz coming from the negative electrode pole, and a 1V signal from the temperature sensor 226 (in the case of a thermistor) that may require filtering of the RF circuit such that the thermistor signal may be sensed and used for generator control. In some embodiments, because of the common ground, the thermistor of the adjacent electrode pair may be used to monitor temperature even without firing the adjacent electrode pair. This may provide the possibility of sensing temperatures proximate to both the distal electrode pad 208 and the proximal electrode pad 236, while firing only one of them.

Referring again to FIG. 3, the electrode pad arrangement of each electrode assembly 140a-d may also enable efficient placement on the expandable member 130. As shown, the electrode assemblies 140a-d may “key” into one another to enable maximum use of the expandable member surface area. This may be accomplished in part by spacing the electrode pads apart by setting the longitudinal length of each intermediate tail. For example, the intermediate tail length electrode assembly 140a may be set to a distance that separates its distal and proximal electrode pads 150a, 170a such that the laterally adjacent proximal electrode pad 170b of the laterally adjacent electrode pad assembly 140b keys next to the intermediate tail 160a of electrode pad assembly 140a. Further, the distal electrode pad 150a of electrode assembly 140a may be keyed between the intermediate tail 160b of electrode assembly 140b and the intermediate tail 160d of electrode assembly 140d. Thus, the length of each intermediate tail 160a-d may also require each electrode pad of any one electrode assembly to be located in non-adjacent treatment zones.

Expandable member or balloon surface area maximization may also be enabled in part by laterally offsetting both electrode pads of each electrode assembly 140a-d. For example, the rightwards lateral offset of each distal electrode pad 150a-d and the leftwards lateral offset of the proximal electrode pad 170a-d allow adjacent electrode pad assemblies to key into one another such that some of the electrode pads may laterally overlap one another. For example, the distal electrode pad 150a of electrode assembly 140a may laterally overlap with proximal electrode pad 170b of electrode assembly 140b. Further, the distal electrode pad 150b of electrode assembly 140b may laterally overlap with the proximal electrode pad 170c of electrode assembly 140c. However, the length of each intermediate tail may prevent circumferential overlap (longitudinal overlap in this view) of the electrode pads, thus maintaining the non-contiguous nature of the treatment zones in the longitudinal direction L-L.

The arrangement and geometry of the electrode pads, as well as the arrangement and geometry of the tails of the flexible circuits may also facilitate folding or otherwise collapsing the balloon into a relatively compact un-expanded state. For instance, in embodiments with an expanded diameter of up to about 10 mm, the device in an un-expanded state may have as low as an about 1 mm diameter.

Some embodiments may utilize a standard electrode assembly having identical dimensions and construction, wherein the number and relative position of electrode assemblies on an outer surface of an expandable member or a balloon becomes a function of the expandable member or balloon diameter and/or length while electrode assembly geometries remain unchanged amongst various expandable member or balloon sizes. The relative positioning of electrode assemblies relative to the expandable member or balloon diameter and/or length may then be determined by the desired degree or avoidance of circumferential and/or axial overlap of adjacent electrode pads of neighboring electrode assemblies on an expandable member or a balloon of a given size. In other embodiments, however, all of the electrode assemblies on the expandable member or balloon may not necessarily be identical.

The system 100 may be used to perform a method of treatment in accordance with one non-limiting embodiment of the disclosure. For example, the control unit 110 may be operationally coupled to the ablation device 120, which may be inserted into a body passageway such that an expandable member 130 (having a plurality of electrode assemblies) may be placed adjacent to a first section of the body passageway where therapy is required. Placement of the ablation device 120 at the first section of the body passageway where therapy is required may be performed according to conventional methods, e.g., over a guidewire under fluoroscopic guidance. Once inserted, the expandable member 130 may be made to expand from a collapsed delivery configuration to an expanded configuration, for example by pressurizing fluid from about 2-10 atm in the case of a balloon. This may cause the electrodes and/or electrode assemblies of the expandable member 130 to come into contact with the first section of the body passageway.

In some embodiments, the control unit 110 may measure impedance at the electrode assemblies to confirm apposition of the electrodes with the body passageway. In at least some of these embodiments, the treatment may proceed even if apposition is not sensed for all of the electrodes. For instance, in some embodiments, the treatment may proceed if apposition is sensed for 50% or more of the electrodes, and may allow for less than complete uniformity of apposition circumferentially and/or axially. For example, in some instances the catheter may be positioned such that one or more of the proximal electrodes are in the aorta A and exposed to blood, and impedance sensed for such electrodes may not fall within a pre-designated range (such as, for example, 500-1600 ohms), indicating an absence of tissue apposition for those electrodes. In some instances, the system may allow for user authorization to proceed with the treatment even if there is less than uniform electrode/tissue apposition. Subsequently, the control unit 110 may activate the electrodes to create a corresponding number of lesions. During activation of the electrodes, the control unit 110 may use temperature sensors of the electrode pads to monitor heat of the electrode and/or the tissue. In this manner, more or less power may be supplied to each electrode pad as needed during treatment.

In some embodiments, the control unit 110 may apply a uniform standard for determining apposition to all the electrodes of the ablation device 120. For instance, the control unit 110 may utilize the same pre-designated range of resistance measurements to all of the electrodes. In other instances, however, including some, although not all, monopolar applications, different standards may be applied to different monopolar electrodes for determining apposition. For example, in some monopolar embodiments, each monopolar electrode may define a discrete electrical circuit through the tissue to the common/indifferent electrode (or electrodes), and the characteristics of those circuits (e.g. resistance) may vary significantly based on the distance between the monopolar electrode and common electrode, the tissue characteristics therebetween, and other geometries and characteristics of the device and surrounding tissue. As such, in at least some embodiments, it may be desirable to apply criteria for determining apposition that varies depending on, e.g., the distance between the monopolar electrode and a common ground electrode (e.g. the greater the distance between the two electrodes, the higher the impedance measurement required to determine good apposition). In other embodiments, however, the variance due to these differences in distance and other geometries may be minimal or non-substantive, and a uniform standard may be applied.

After the prescribed therapy in the first section of the body passageway is complete, the expandable member 130 may then be collapsed and moved to an untreated second section of the body passageway where therapy is required to repeat the therapy applied in the first section of the body passageway, and similarly to other sections as needed. The sections may be directly adjacent, or may be separated or spaced apart by some distance.

In some instances, alternative methods will be utilized. For instance, in some embodiments, the treatment may be performed at only a single location in the body passageway, and it may not be necessary to move the expandable member to multiple locations in the body passageway.

Referring to an example of renal hypertension involving the reduction of excessive nerve activity, the system 100 may be used to effect a non-piercing, non-ablating way to direct energy to affect nerve activity. Accordingly, the body passageway may be a renal artery surrounded by nervous tissue. Electrodes on the expandable member 130 may be powered to deliver energy in the known direction of a nerve to be affected, the depth of energy penetration being a function of energy dosage, electrode type (e.g. monopolar vs. bipolar) and electrode geometry. U.S. Patent Application Publication No. 2008/0188912 entitled “System for Inducing Desirable Temperature Effects on Body Tissue”, the full disclosure of which is incorporated herein by reference, describes some considerations for electrode geometry and the volume of tissue treatment zones that may be taken into account in some, although not necessarily all, embodiments. In some instances, empirical analysis may be used to determine the impedance characteristics of nervous tissue such that the ablation device 120 may be used to first characterize and then treat tissue in a targeted manner. The delivery and regulation of energy may further involve accumulated damage modeling, as well.

As shown, each lesion may be created in a corresponding treatment zone A-D of the expandable member 130. Accordingly, any lesion made in one particular treatment A-D zone may not circumferentially overlap with a lesion of an adjacent treatment zone A-D at any point along the operational axis O-O. In some embodiments, a treatment zone of the expandable member 130 may have more than one electrode pad, and thus in such cases, lesions created by those electrode pads may circumferentially overlap. In those cases, more lesions may be required for a particular anatomy or a pair of electrode pads may be required for performing a diagnostic routine before therapy is applied. Regardless, circumferential overlap of electrodes of adjacent treatment zones may not be present.

Depending on the particular remodeling effect required, the control unit may energize the electrodes with about 0.25 to about 5 Watts average power for about 1 to about 180 seconds, or with about 0.25 to about 900 Joules. Higher energy treatments may be done at lower powers and longer durations, such as 0.5 Watts for 90 seconds or 0.25 Watts for 180 seconds. In monopolar embodiments, the control unit may energize the electrodes with up to 30 Watts for up to 5 minutes, depending on electrode configuration and distance between the electrodes and the common ground. A shorter distance may provide for lower energy for a shorter period of time because energy travels over more localized area with fewer conductive losses. In an example embodiment for use in renal denervation, energy may be delivered for about 30 seconds at a treatment setting of about 5 Watts, such that treatment zones may be heated to about 68° C. during treatment. As stated above, power requirements may depend heavily on electrode type and configuration. Generally, with wider electrode spacing, more power may be required, in which case the average power could be higher than 5 Watts, and the total energy could exceed 45 Joules. Likewise, using a shorter or smaller electrode pair may require scaling the average power down, and the total energy could be less than 4 Joules. The power and duration may be, in some instances, calibrated to be less than enough to cause severe damage, and particularly less than enough to ablate diseased tissue within a blood vessel. The mechanisms of ablating atherosclerotic material within a blood vessel have been well described, including by Slager et al. in an article entitled, “Vaporization of Atherosclerotic Plaque by Spark Erosion” in J. of Amer. Cardiol. (June, 1985), on pp. 1382-6; and by Stephen M. Fry in “Thermal and Disruptive Angioplasty: a Physician's Guide”; Strategic Business Development, Inc., (1990), the full disclosure of which is incorporated herein by reference.

In some embodiments, energy treatments applied to one or both of the patient's renal arteries may be applied at higher levels than would be possible in other passageways of the body without deleterious effects. For instance, peripheral and coronary arteries of the body may be susceptible to a deleterious long-term occlusive response if subjected to heating above a certain thermal response limit. It has been discovered that renal arteries, however, can be subjected to heating above such a thermal response limit without deleterious effect.

In some embodiments, the electrode(s) described herein may be energized to assess and then selectively treat targeted tissue to achieve a desired therapeutic result by a remodeling of the treated tissue. For example, tissue signature may be used to identify tissue treatment regions with the use of impedance measurements. Impedance measurements utilizing circumferentially spaced electrodes within a body passage may be used to analyze tissue. Impedance measurements between pairs of adjacent electrodes may differ when the current path passes through diseased tissue, and when it passes through healthy tissues of a luminal wall, for example. Hence, impedance measurements between the electrodes on either side of diseased tissue may indicate a lesion or other type of targeted tissue, while measurements between other pairs of adjacent electrodes may indicate healthy tissue. Other characterization, such as intravascular ultrasound, optical coherence tomography, or the like, may be used to identify regions to be treated either in conjunction with, or as an alternative to, impedance measurements. In some instances, it may be desirable to obtain baseline measurements of the tissues to be treated to help differentiate adjacent tissues, as the tissue signatures and/or signature profiles may differ from person to person. Additionally, the tissue signatures and/or signature profile curves may be normalized to facilitate identification of the relevant slopes, offsets, and the like between different tissues. Impedance measurements may be achieved at one or more frequencies, ideally two different frequencies (low and high). Low frequency measurement may be done in range of about 1-10 kHz, or about 4-5 kHz and high frequency measurement may be done in range of about 300 kHz-1 MHz, or between about 750 kHz-1 MHz. Lower frequency measurement mainly represents the resistive component of impedance and may correlate closely with tissue temperature where higher frequency measurement may represent the capacitive component of impedance and may correlate with destruction and changes in cell composition.

Phase angle shift between the resistive and capacitive components of impedance may also occur due to peak changes between current and voltage as result of capacitive and resistive changes of impedance. The phase angle shift may also be monitored as means of assessing tissue contact and lesion formation during RF denervation.

In some embodiments, remodeling of a body lumen or passageway may be performed by gentle heating in combination with gentle or standard dilation. For example, an angioplasty balloon catheter structure having electrodes disposed thereon may apply electrical potentials to the vessel wall before, during, and/or after dilation, optionally in combination with dilation pressures which are at or significantly lower than standard, unheated angioplasty dilation pressures. Where balloon inflation pressures of 10-16 atmospheres may, for example, be appropriate for standard angioplasty dilation of a particular lesion, modified dilation treatments combined with appropriate electrical potentials (through flexible circuit electrodes on the balloon, electrodes deposited directly on the balloon structure, or the like) described herein may employ from about 10-16 atmospheres or may be effected with pressures of about 6 atmospheres or less, and possibly as low as about 1 to 2 atmospheres. Such moderate dilation pressures may (or may not) be combined with one or more aspects of the tissue characterization, tuned energy, eccentric treatments, and other treatment aspects described herein for treatment of body lumens, the circulatory system, and diseases of the peripheral vasculature.

In many embodiments, gentle heating energy added before, during, and/or after dilation of a body passageway may increase dilation effectiveness while lowering complications. In some embodiments, such controlled heating with a balloon may exhibit a reduction in recoil, providing at least some of the benefits of a stent-like expansion without the disadvantages of an implant. Benefits of the heating may be enhanced (and/or complications inhibited) by limiting heating of the adventitial layer below a deleterious response threshold. In many cases, such heating of the intima and/or media may be provided using heating times of less than about 10 seconds, often being less than 3 (or even 2) seconds. In other cases, very low power may be used for longer durations. Efficient coupling of the energy to the target tissue by matching the driving potential of the circuit to the target tissue phase angle may enhance desirable heating efficiency, effectively maximizing the area under the electrical power curve. The matching of the phase angle need not be absolute, and while complete phase matching to a characterized target tissue may have benefits, alternative systems may pre-set appropriate potentials to substantially match typical target tissues; though the actual phase angles may not be matched precisely, heating localization within the target tissues may be significantly better than using a standard power form.

In some embodiments, monopolar (unipolar) RF energy application may be delivered between any of the electrodes on the expandable member and a common ground or return electrode positioned on the outside skin or on the device itself. Monoploar RF may be desirable in areas where deep lesions are required. For example, in a monopolar application, each electrode pair may be powered with positive polarity rather than having one positive pole and one negative pole per pair. In some embodiments, a combination of monopolar and bipolar RF energy application may be done where lesions of various depth/size can be selectively achieved by varying the polarity of the electrodes of the pair.

The application of RF energy may be controlled so as to limit a temperature of target and/or collateral tissues, for example, limiting the heating of target tissue such that neither the target tissue nor the collateral tissue sustains irreversible thermal damage. In some embodiments, the surface temperature range may be from about 50° C. to about 90° C. For gentle heating, the surface temperature may range from about 50° C. to about 70° C., while for more aggressive heating, the surface temperature may range from about 70° C. to about 90° C. Limiting heating so as to inhibit heating of collateral tissues to less than a surface temperature in a range from about 50° C. to about 70° C., such that the bulk tissue temperature remains mostly below about 50° C. to about 55° C., may inhibit an immune response that might otherwise lead to stenosis, thermal damage, or the like. Relatively mild surface temperatures between about 50° C. and about 70° C. may be sufficient to denature and break protein bonds during treatment, immediately after treatment, and/or more than one hour, more than one day, more than one week, or even more than one month after the treatment through a healing response of the tissue to the treatment so as to provide a bigger vessel lumen and improved blood flow.

In some embodiments, the target temperature may vary during the treatment, and may be, for instance, a function of treatment time. One possible target temperature profile may include a treatment with a duration of 30 seconds and a twelve second ramp up from nominal body temperature to a maximum target temperature of about 68° C. During the twelve second ramp up phase, the target temperature profile may be defined by a quadratic equation in which target temperature (T) is a function of time (t). The coefficients of the equation may be set such that the ramp from nominal body temperature to about 68° C. may follow a path analogous to the trajectory of a projectile reaching the maximum height of its arc of travel under the influence of gravity. In other words, the ramp may be set such that there may be a constant deceleration in the ramp of temperature (d²T/dt²) and a linearly decreasing slope (dT/dt) in the temperature increase as 12 seconds and 68° C. are reached. Such a profile, with its gradual decrease in slope as it approaches 68° C., may facilitate minimizing over and/or undershoot of the set target temperature for the remainder of the treatment. In some embodiments, the target temperature profile may be equally suitable for bipolar or monopolar treatments, although, in at least some monopolar embodiments, treatment time may be increased. Other target temperature profiles utilizing different durations of time (i.e., 3 seconds, 5 seconds, 8 seconds, 12 seconds, 17 seconds, etc.) and set target temperatures (55° C., 60° C., 65° C., 70° C., 75° C., etc.) in various combinations may be used as desired. For each of the target temperature profiles considered, a temperature ramp embodying or approximating a quadratic equation may be utilized, however, any function or other profile that efficiently heats tissue, optimizes treatment time, and avoids thermal damage to target tissue may be used. However, in still other embodiments, it will not be necessary to utilize a temperature profile that achieves all of these goals. For instance and without limitation, in at least some embodiments, optimization of treatment time may not be essential.

A control method may be executed using the processing functionality of the control unit 110 of FIG. 1 and/or control software, described in further detail above, or in other manners. In at least some instances, the control method may provide for fine regulation of temperature or other treatment parameter(s) at the various treatment sites of the device, while utilizing a relatively simple and robust energy generator to simultaneously energize several of the electrodes or other delivery sites at a single output setting (e.g. voltage), which may minimize cost, size and complexity of the system. The control method may minimize deviation from target temperature or other treatment parameter(s), and hence minimize variation in demand on the energy generator (e.g. voltage demand) during any time slice of the treatment.

In some embodiments, it may be desirable to regulate the application of RF or other energy based on target temperature profiles such as those described above to provide for a gentle, controlled, heating that avoids application of high instantaneous power and, at a microscopic level, associated tissue searing or other damage, which could undesirably result in heat block or otherwise cause a net reduction in thermal conduction heat transfer at the device/tissue interface. In other words, by avoiding higher swings in temperature and the resultant heavier instantaneous application of energy to reestablish temperature near the target temperature, tissue integrity at the immediate interface location may be preserved. Tissue desiccation may result in a net loss of thermal conductivity, resulting in reduced effective transfer of gentle, therapeutic delivery of energy to target tissues beyond the electrode/tissue interface.

Those of skill in the art will appreciate that although a particular control method may be presented for purposes of illustration in the context of the particular electrosurgical devices already described above, that these control methods and similar methods could be beneficially applied to other electro-surgical devices.

In general, the control method may seek to maintain the various treatment sites at a pre-defined target temperature, such as at one of the target temperature profiles discussed above. In some embodiments, the control method may maintain the treatment site(s) at the pre-defined target temperature primarily by regulating output voltage of the RF generator and determining which of the electrodes will by energized at a given time slice (e.g. by switching particular electrodes on or off for that cycle).

The output setting of the generator and switching of the electrodes may be determined by a feedback loop that takes into account measured temperature as well as previous desired output settings. During a particular treatment cycle (e.g. a 25 millisecond slice of the treatment), each of the electrodes may be identified for one of three states: off, energized, or measuring. In some embodiments, electrodes may only be in energized and/or measuring states (an electrode that is energized may also be measuring) if they meet certain criteria, with the default electrode state being off. Electrodes that have been identified as energized or measuring electrodes may have voltage applied or be detecting temperature signals for a portion of the cycle, or for the entire cycle.

In some embodiments, the control method may be designed to keep as many candidate electrodes as possible as close to target temperature as possible while minimizing variations in temperature and hence minimizing variations in voltage demand from treatment cycle to treatment cycle.

Each electrode may be initially set to off. At a next step, one of the electrodes may be designated as a primary electrode for that treatment cycle. As discussed in further detail below, during the treatment, the primary electrode designated may vary from treatment cycle to treatment cycle (e.g. cycle through all of the available electrodes). The determination of which electrode may be designated as the primary electrode may be done by accessing a look-up table or using any other suitable functionality for identifying a primary electrode and varying the choice of primary electrode from treatment cycle to treatment cycle.

Additionally, at the next step discussed above, additional electrodes may also be designated as candidate electrodes for energization and/or measuring during that treatment cycle. The additional electrodes designated may be candidates by virtue of being in a certain relationship or lacking a certain relationship relative to the designated primary electrode for that treatment cycle.

For instance, in some bipolar electrode embodiments, some of the electrodes on the ablation device may be arranged in a manner such that there may be a potential for current leakage between the primary electrode and those other electrodes if both the primary electrode and those additional electrodes are energized simultaneously in a treatment cycle, which may undesirably cause interference with the temperature measurement by the associated temperature sensor, imprecision in the amount of energy delivered at each electrode, or other undesirable consequences. For instance, in the embodiment illustrated in FIG. 3, if electrode pad 150c is designated as a primary electrode, electrode pads 150d and 170d, which have negative poles immediately adjacent or proximate the positive pole of electrode pad 150c, may be considered to be not candidates for measuring and/or energization for that particular treatment cycle, since they are leakage-inducingly proximate to the designated primary electrode. Additionally, in this embodiment, electrode pad 150b, which may have a positive pole immediately adjacent or proximate the negative pole of electrode pad 150c, may be considered to not be a candidate, since it may also be leakage-inducingly proximate to the designated primary electrode. Furthermore, in this particular embodiment, electrode pad 170b may also be considered a non-candidate because it may be on the same flex structure as the leakage-inducingly proximate electrode pad 150b. Finally, in this particular embodiment, electrode pads 150a and 170a may be considered candidates because they are adjacent non-candidates.

As another non-limiting example, in some monopolar electrode embodiments, the candidate electrodes may be the monopolar electrodes that have similar measured or estimated electrical circuit properties to one or more measured or estimated properties of the electrical circuit associated with the primary electrode. In other words, in some monopolar systems, it may be desirable to only simultaneously energize monopolar electrodes that define substantially similar electrical circuits to the electrical circuit defined by the primary monopolar electrode (e.g. the circuit defined by the monopolar electrode, the common electrode, and a pathway through the patient's tissue). In some instances, this may facilitate uniformity in current flow during energization. In other embodiments, a pre-defined table or other listing or association may determine which electrodes are candidate electrodes based on the current primary electrode.

In at least some embodiments, switches associated with non-candidates may be opened to isolate the non-candidates from the rest of the system's circuitry. This switching, in at least some embodiments, may also or alternatively be used to otherwise maximize the number of available electrode pairs available for energization provided that a common ground between pairs is not affected by the switching off.

In other embodiments, the ablation device may be configured to avoid the potential for leakage or otherwise take such leakage into account, and, accordingly, all the electrodes of the device may be candidates for energization and/or measuring during a treatment cycle.

In some embodiments, the assignment of an electrode as either the primary electrode, candidate, or non-candidate may be determined by a sequence matrix or look up table in an array that identifies the status of each of the electrodes and an order for the designation of primary electrodes. In one non-limiting embodiment, the primary electrode designation cycles circumferentially through the proximate electrodes and then circumferentially through the distal electrodes (e.g. in FIG. 3, the sequence may be 170a, b, c, d, 150a, b, c, d). However, any pattern or other methodology could be used including ones that optimize distance between the next in sequence, the nearness of next in sequence, or the evenness of distribution.

In some embodiments, additional conditions may result in a particular electrode being set to off for a particular treatment cycle and/or for the remainder of the treatment. For instance, as discussed below, during the course of treatment, as much as 4° C. temperature overshoot may be allowed (e.g., even if such overshoot results in the electrode not being energized, it may not necessarily be set to off and may still be available for measuring); however, in at least some embodiments, if eight consecutive treatment cycles measure temperature overshoot for a particular electrode, that electrode may be set to off for the remainder of the treatment, with the treatment otherwise continuing and without otherwise changing the control loop process discussed below.

At a next step, target voltages for each of the primary and other candidate electrodes may be determined. In some embodiments, a target voltage for a particular electrode may be determined based on a temperature error associated with the treatment site of that electrode as well as the last target voltage calculated (although not necessarily applied) for that electrode. Temperature error may be calculated by measuring the current temperature at the treatment site (e.g. utilizing the temperature sensor associated with the electrode proximate that treatment site) and determining the difference between the measured temperature and the target temperature for that instant of time in the treatment.

Those of skill in the art will appreciate that while some embodiments are described as using voltage as a control variable, power could be used as an alternative to voltage for the control variable, based on, for instance, a known relationship between power and voltage (i.e. power equaling voltage times current or impedance).

One embodiment may include a sub-routine for determining a target voltage for an electrode. For example, one step may include calculating a temperature error from target (T_e) by subtracting the target temperature at that time (T_g) from the actual temperature (T) (e.g. as measured by a thermistor associated with that electrode). Subsequently, it may be determined whether the temperature error calculated at the calculating step is greater than 4° C. (i.e. if the target temperature is 68° C., determining if the temperature as measured by the thermistor is above 72° C.). If the temperature error is greater than 4° C., the sub-routine may assign that electrode a target voltage of zero for that treatment cycle. If the temperature error is not greater than 4° C., the subroutine may proceed to a next step and determine whether the temperature error is greater than 2° C. If the temperature error is greater than 2° C., the sub-routine may assign that electrode a target voltage of 75% (or another percentage) of the last assigned target voltage for that electrode. If the temperature error is not greater than 2° C., the sub-routine may assign a target voltage for that electrode based on the equation:

V=K_LV_L+K_PT_e+K_I∫^t_{t-n sec}T_{e AVE}

- where:
  - V is the target voltage;
  - T_eis a temperature error from target;
  - V_Lis the last assigned electrode voltage;
  - K_L, K_P, and K_Iare constants; and
  - n is a time value ranging from 0 to t seconds.

In some embodiments, the equation used may be:

$V = 0.75 V_{L} + K_{p} T_{e} + K_{I} \int_{t - n \sec}^{t} T_{e AVE}$

- where:
  - V is the target voltage;
  - T_eis the temperature error from target;
  - V_Lis the last assigned electrode voltage;
  - K_Pis a constant from proportionate control; and
  - K_Iis a constant from integral control.

In some embodiments, it may be beneficial to use only the last assigned electrode voltage for determining a target voltage, rather than utilizing averages of voltages or voltages from earlier treatment cycles, as, in some cases, use of earlier voltages may be a source for computational error in embodiments that focus on fine control of the target temperature.

Once target voltages are determined for the primary electrode and other candidate electrodes, it may be determined whether the target voltage for the primary electrode is greater than zero. If not, the output voltage of the RF generator may be set for that treatment cycle to the lowest target voltage determined for the other candidate electrodes. If the target voltage determined for the primary electrode is greater than zero, the output voltage of the RF generator may be set for that treatment cycle to the target voltage of the primary electrode.

Next, the primary and other candidate electrodes with a target voltage greater than zero may be identified as electrodes to be energized. In alternative embodiments, candidate electrodes other than the primary may only be energized if the target voltages determined for those electrodes is 6V greater than the set voltage. In some embodiments, candidate electrodes other than the primary may only be energized if the target voltages determined for these electrodes are 1, 5 or 10V greater than the set voltage.

Lastly, it may be determined whether the electrodes to be energized are currently at temperatures greater than 68° C. Those electrodes that are at temperatures greater than 68° C. may be switched off or otherwise prevented from being energized in that treatment cycle, and those electrodes otherwise meeting the above criteria may be energized at the set voltage. Subsequently, another treatment cycle begins, and the control method may be repeated until the treatment is complete. In some embodiments, each treatment cycle will be non-overlapping with the previous and next cycles (e.g. the steps of the control method will be completely performed before the next cycle's steps begin), although, in other embodiments, the cycles may be overlapping at least to some extent.

Turning now to FIG. 7, a renal nerve ablation device 300 may include an expandable member 130 that may be disposed at, on, about, or near a distal region of the elongate tubular member or catheter shaft 122, as discussed above. In some embodiments, the proximal waist 136 of the expandable member 130 may be fixedly attached to the elongate tubular member or catheter shaft 122. In some embodiments, the renal nerve ablation device 300 includes a ride-along electrode support 305 with one or more electrodes. In some embodiments, the electrode support 305 may be fixedly attached to the elongate tubular member or catheter shaft 122. The electrode support 305 may be free from attachment to the body 135 of the expandable member 130. In some embodiments, the electrode support 305 may be expandable from a collapsed delivery state to an expanded state, such as a basket or a plurality of struts or elongate members, for example. The electrode support 305 may include one or more flexible elongate members 310 each having a proximal end 320 which may be fixedly attached to the catheter shaft 122. In some embodiments, a plurality of elongate members 310 have proximal ends 320 fixedly attached to the catheter shaft 122. In some embodiments, the distal ends 315 of the elongate members 310 are free of any attachment to the catheter shaft 122 and expandable member 130. In other embodiments, the distal ends 315 may be connected to each other, as shown in FIG. 7, and/or to a connection member or ring (not shown). In some embodiments, elongate members 310 are free from attachment to the catheter shaft 122 or to the expandable member 130 at least from a point distal of the proximal ends 320 and extending to the distal ends 315. The elongate members 310 may be connected to the catheter shaft 122 and unconnected to the expandable member 130. In some embodiments, proximal ends 320 of the elongate members 310 may be attached to the proximal waist 136 of the expandable member 130 in a region of connection between the proximal waist 136 and the catheter shaft 122.

In some embodiments, the electrode support 305 is a separate element from the expandable member 130 and is unconnected to the expandable member 130. As shown in FIG. 8, the electrode support 305 may be fixedly connected to a separate elongate element or catheter shaft 322. In some embodiments, the electrode support 305 may be deliverable separately from the expandable member 130. In this embodiment, the electrode support 305 may be delivered to a body lumen, followed by delivery of the expandable member 130 through catheter 322. Once the expandable member 130 is positioned within the electrode support 305, the expandable member 130 is expanded thereby expanding the electrode support 305 and placing the electrode assemblies 325 on the electrode support 305 in contact with the interior of the body lumen. Following treatment with the electrode assemblies 325, the expandable member 130 may be contracted. The lack of attachment between the electrode support 305 and the majority of the expandable member 130 allows the expandable member 130 to be deflated in any manner. For example, the expandable member 130 may be deflated via a vacuum source, re-folded or twisted by applying torque to at least a portion of the expandable member 130, or by being withdrawn back into a guide catheter 14. The contracted or deflated expandable member 130 may be withdrawn first followed by withdrawal of the electrode support 305. Alternatively, the contracted expandable member 130 and the electrode support 305 may be removed simultaneously. The separate electrode support 305 does not interfere with deflation, contraction, twisting, or re-folding of the expandable member 130. The elongate members 310 collapse into their pre-expansion state for withdrawal into a guide catheter 14.

In some embodiments, the electrode support 305 is disposed over the expandable member 130 and expands when the expandable member 130 is expanded. The elongate members 310 are not attached to the expandable member 130 and during expansion the elongate members 310 move farther apart from each other. In some embodiments, the electrode support 305 may be used with a variety of sizes of expandable member 130. The elongate members 310 move farther apart as the diameter of the expandable member 130 increases. Expansion of the expandable member 130 within a body lumen forces the elongate members into contact with the inner walls of the body lumen. Upon contraction of the expandable member 130, the electrode support 305 may remain in substantially the expanded configuration, allowing the expandable member 130 to contract, twist, fold, or otherwise attain a configuration suitable for retraction into a delivery sheath or catheter. The unattached electrode support 305 does not interfere with expansion and contraction of the expandable member. In some embodiments, the electrode support 305 collapses or folds onto the previously folded or collapsed expandable member 130 as the entire ablation device 300 is retracted into a delivery sheath or catheter when the catheter 122 is withdraw proximally. In other embodiments, the expandable member and electrode support 305 are withdrawn in order to collapse both elements substantially simultaneously. In other embodiments, the electrode support 305 may be biased in a collapsed configuration, such that when the expandable member 130 is contracted, the electrode support 305 automatically returns to a contracted configuration.

The electrode support 305 may include a plurality of electrode assemblies 325. In some embodiments, each elongate member 310 may contain one or more electrode assemblies 325. In some embodiments, each electrode assembly 325 may include a ground electrode 330, an active electrode 335, and a sensor element 340. In some embodiments, each elongate member 310 may have electrode assemblies 325 that extend from alternating sides, as shown in FIG. 7. In some embodiments, the electrodes and sensors of each electrode assembly 325 may be arranged as shown in FIG. 4. In some embodiments, the electrode support 305 may be made up of one or more elongate members 310 extending generally parallel to the longitudinal axis of the expandable member 130, as shown in FIG. 7. In other embodiments, the elongate members 310 may be twisted or canted at an angle from the longitudinal axis.

In some embodiments, the expandable member 132 has one or more channels 134 extending along a length of the expandable member 132. The channels 134 are configured to remain when the expandable member 132 is expanded. When the expandable member 132 is placed within a body lumen such as a blood vessel, and expanded, the channels 134 allow partial fluid flow across the expandable member 132. The channels 134 may be substantially parallel to a longitudinal axis of the expandable member 132, or the channels may be arranged in other configurations. In the embodiment illustrated in FIGS. 9-11, an expandable member 132 has three channels 134 extending in a spiral along the expandable member 132. Any number of channels 134 may be included in the expandable member 132. The channels 134 may be spaced apart in a manner that allows for the elongate members 360 of the electrode support 355 to be disposed between channels 134. In some embodiments, the elongate members 360 extend in a spiral matching the angle of the channels 134.

Turning now to FIG. 12, in some embodiments, a renal nerve ablation device 400 may include a ride-along electrode support 405 in which a plurality of flexible elongate members 410 extend around an expandable member 130 at an angle with respect to the longitudinal axis. As discussed above, the expandable member 130 may be disposed at, on, about, or near a distal end of the elongate tubular member or catheter shaft 122. In some embodiments, the electrode support 405 may be fixedly attached to the elongate tubular member or catheter shaft 122, and free from attachment to the body 135 of the expandable member 130. In some embodiments, the electrode support 405 may be expandable from a collapsed delivery state to an expanded state. The electrode support 405 may include one or more electrode assemblies 425. The electrode assembly 425 may include a plurality of flexible elongate members 410 with proximal ends 420 fixedly attached to the catheter shaft 122. In the embodiment illustrated in FIG. 12, the electrode assembly 425 has three elongate members 410 connected to each other only at their proximal ends 420. The distal ends 415 of the elongate members 410 may be free of any attachment to each other and to the expandable member 130. In some embodiments, proximal ends 420 of the elongate members 410 may be attached to the proximal waist 136 of the expandable member 130 in a region of connection between the proximal waist 136 and the catheter shaft 122.

In some embodiments, the electrode support 405 is disposed over the expandable member 130 and expands when the expandable member 130 is expanded. The elongate members 410 are not attached to the expandable member 130 and during expansion the elongate members 410 move farther apart from each other. The electrode support 405 may include a plurality of electrode assemblies 425. In some embodiments, each electrode assembly 425 includes a plurality of elongate members 410.

In some embodiments, each electrode assembly 425 may include three elongate members 410. A first elongate member 410 may carry a plurality of ground electrodes 430, a second elongate member 410 may carry a plurality of active electrodes 435, and a third elongate member 410 may carry a plurality of sensor elements 440. In some embodiments, the ground electrodes 430, active electrodes 435, and sensor elements 440 are grouped longitudinally on adjacent elongate members 410. In some embodiments, a single sensor element 440 may be disposed on an elongate member 410 between a first elongate member 410 with a plurality of ground electrodes 430 and a second elongate member 410 with a plurality of active electrodes 435. In some embodiments, such as that illustrated in FIG. 12, the elongate members 410 may be twisted or canted at an angle from the longitudinal axis. In some embodiments, the electrode support 405 includes two electrode assemblies 425, positioned on substantially opposite sides of the expandable member 130. In other embodiments, the electrode support 405 includes three electrode assemblies 425 positioned at substantially equal distances from each other around the expandable member 130. In some embodiments, the elongate members 410 are substantially parallel.

In some embodiments, the axial position of groups of ground 430 and active 435 electrodes and sensor elements 440 are offset on adjacent electrode assemblies 425. For example, as shown in FIG. 12, in some embodiments, the electrode assemblies may be arranged on the expandable member 130, shown here in an expanded state, according to a pair of generally cylindrical treatment zones A and B. In other embodiments, the expandable member 130 or other components of the treatment system may include additional electrode assemblies that are not in a treatment zone or are otherwise not used or configured to deliver a treatment energy.

The treatment zones A and B and associated electrode assemblies 425a-c are further illustrated in FIG. 13, which is an “unrolled” depiction of a portion of the electrode support 405 of FIG. 12. The treatment zones A and B may be longitudinally adjacent to one another along longitudinal axis L-L, and may be configured such that energy applied by the electrode assemblies create treatments that do not overlap. Treatments applied by the longitudinally adjacent bipolar electrode assemblies 425a-c may be circumferentially non-continuous along longitudinal axis L-L. For example, with reference to FIG. 13, lesions created in treatment zone A may in some embodiments minimize overlap about a circumference (laterally with respect to L-L in this view) with lesions created in treatment zone B. In other embodiments, however, the energy applied by the electrode assemblies, such as the electrode assemblies shown in FIG. 13, may overlap, longitudinally, circumferentially, and/or in other ways, to at least some extent.

In some embodiments, the sensor element 440 may be disposed adjacent to the ground electrode 430 and/or the active electrode 435. In some embodiments, the ground electrode 430, the active electrode 435, and/or the sensor element 440 may extend along a length of the expandable member 130. In some embodiments, the ground electrode 430, the active electrode 435, and/or the sensor element 440 may extend along substantially a full length of the expandable member 130.

Turning to FIG. 14, in some embodiments, a renal nerve ablation device 500 may include a ride-along electrode support 505 in which a plurality of flexible elongate members 510 are disposed in a helical or spiral pattern or orientation along an outer surface of the expandable member 130. As discussed above, the expandable member 130 may be disposed at, on, about, or near a distal end of the elongate tubular member or catheter shaft 122. In some embodiments, the electrode support 505 may be fixedly attached to the elongate tubular member or catheter shaft 122 and free from attachment to the body 135 of the expandable member 130. In some embodiments, the electrode support 505 may be expandable from a collapsed delivery state to an expanded state. The electrode support 505 may include an electrode assembly 525 which may include a plurality of flexible elongate members 510 with proximal ends 520 fixedly attached to the catheter shaft 122. In the embodiment illustrated in FIG. 14, the electrode assembly 525 has three elongate members 510 connected to each other only at their proximal ends 520 and distal ends 515. In some embodiments, proximal ends 520 of the elongate members 510 may be attached to the proximal waist 136 of the expandable member 130 in a region of connection between the proximal waist 136 and the catheter shaft 122.

In some embodiments, the electrode support 505 is disposed over the expandable member 130 and expands when the expandable member 130 is expanded. The elongate members 510 are free from attachment to the body 135 of the expandable member 130 and are free from attachment to each other except at their distal 515 and proximal ends 520, allowing the elongate members 510 to move farther apart from each other during expansion. The electrode support 505 may be used in combination with expandable members 130 of varying expanded sizes. The elongate members 510 may be attached to each other at their distal 515 and proximal 520 ends. In some embodiments, the distal ends 515 of the elongate members 510 may be attached to the distal waist 137 of the expandable member 130 and the proximal ends 520 of the elongate members 510 may be attached to proximal waist 136 of the expandable member 130. In other embodiments, the distal 515 and proximal 520 ends of the elongate members 510 may be attached to the catheter shaft 122. The electrode support 505 may include a plurality of electrode assemblies 525 spaced apart axially along the electrode support 505.

In some embodiments, the electrode assembly 525 may include three elongate members 510. A first elongate member 510 may carry a plurality of ground electrodes 530, a second elongate member 510 may carry a plurality of active electrodes 535, and a third elongate member 510 may carry a plurality of sensor elements 540. In some embodiments, the ground electrodes 530, active electrodes 535, and sensor elements 540 are grouped axially on adjacent elongate members 510, as illustrated in FIG. 14. In some embodiments, a single sensor element 540 may be disposed on an elongate member 510 between a first elongate member 510 with a plurality of ground electrodes 530 and a second elongate member 510 with a plurality of active electrodes 535. In some embodiments, such as that illustrated in FIG. 14, the elongate members 510 may be twisted or canted at an angle from the longitudinal axis, forming a helix. In some embodiments, the electrode support 505 includes one or more elongate support 511 disposed in a helical or spiral pattern or orientation along an outer surface of the expandable member 130. The elongate supports 511 may balance the electrode assembly 525. The elongate supports 511 may be free of electrodes or other elements. In some embodiments, two sets of three elongate supports 511 may be present. The elongate supports 511 may be connected to each other only at their proximal and distal ends and may be free of attachment to the body 135 of the expandable member 130. The distal ends 515 of the elongate members 510 may be connected to distal ends of the elongate supports 511.

In some embodiments, the electrode support 505 includes circuitry (not shown) connected to the ground electrodes 530, active electrodes 535, and sensor elements 540. In some embodiments, the circuitry extends from each electrode proximally to the catheter shaft 122. In some embodiments, a first portion of the circuitry extends proximally along the elongate members 510 to the catheter shaft 122, and a second portion of the circuitry extends distally along the elongate members 510 to the distal ends 515 of the elongate members 510. The second portion of the circuitry may then be shifted to one or more of the elongate supports 511 and extend proximally along the one or more elongate supports 511 to the catheter shaft 122. Such a split distribution of the circuitry may allow for narrower and more flexible elongate members 510.

The ground electrode 530, the active electrode 535, and the sensor element 540 may be oriented generally parallel to each other. The helical or spiral pattern or orientation may be arranged such that a plane placed normal or perpendicular to the longitudinal axis L-L of the expandable member 130 may intersect the electrode assembly 525, the ground electrode 530, the active electrode 535, and/or the sensor element 540 at a single location such that at no location along the length of the expandable member 130 does the electrode assembly 525, the ground electrode 530, the active electrode 535, and/or the sensor element 540 overlap itself longitudinally. Other arrangements, however, are contemplated.

The helical orientation along the length of the expandable member 130 forms at least one complete (360 degree) circumferential loop within the lumen or vessel that the expandable member 130 is positioned. The electrodes provide heating at a location within the tissue surrounding the body passageway without damaging the wall of the body passageway in order to disrupt the nerves located in the tissue surrounding the body passageway wall. A helical orientation is desirable to help avoid an increased risk of stenosis that may be present when electrodes are disposed within a single plane normal to a longitudinal axis of the body passageway (i.e., a circular electrode or group of electrodes).

In some embodiments, the renal nerve ablation device 300, 400, 500 may include a single ground electrode 330, 430, 530 and a single active electrode 335, 435, 535. Accordingly, the ground electrode 330, 430, 530 and the active electrode 335, 435, 535 may combine to form a bipolar electrode pair. When the renal nerve ablation device 300, 400, 500 is energized, such as in the manner(s) described above, RF energy or other suitable energy may pass from the active electrode 335, 435, 535 to the ground electrode 330, 430, 530, thereby creating a corresponding lesion or lesions along a body passageway within which the expandable member 130 has been positioned. The sensor element 340, 440, 540 may be positioned between the ground electrode 330, 430, 530 and the active electrode 335, 435, 535. The sensor element 340, 440, 540 may include at least one temperature sensor, such as a thermistor or thermocouple, positioned on the outer surface of the expandable member 130. The at least one temperature sensor may be positioned between the ground electrode 330, 430, 530 and the active electrode 335, 435, 535, and may be configured to monitor the temperature of the target tissue, the active and ground electrodes, or both, as discussed above. In some embodiments, the at least one temperature sensor may include a plurality of temperature sensors configured to monitor the temperature of the target tissue, the active electrodes, the ground electrodes, or any combination thereof, at a plurality of locations along the length of the expandable member 130.

Turning now to FIG. 15, in some embodiments, a renal nerve ablation device 600 may include an electrode support 605 similar to that discussed above with regard to the embodiment of FIG. 14, but in which the electrode assembly 625 may lack a ground electrode, or the ground electrode may not be connected to the control unit 110, such that the active electrode 635 may form a monopolar electrode. As discussed above, the electrode support 605 may include a plurality of flexible elongate members 610 disposed in a helical or spiral pattern or orientation along an outer surface of the expandable member 130. In some embodiments, the electrode support 605 may be fixedly attached to the elongate tubular member or catheter shaft 122. In some embodiments, the electrode support 605 may be expandable from a collapsed delivery state to an expanded state. The electrode support 605 may include an electrode assembly 625 which may include a plurality of flexible elongate members 610 with proximal ends 620 fixedly attached to the catheter shaft 122. In the embodiment illustrated in FIG. 15, the electrode assembly 625 has three elongate members 610 connected to each other only at their proximal ends 620 and distal ends 615. In some embodiments, proximal ends 620 of the elongate members 610 may be attached to the proximal waist 136 of the expandable member 130 in a region of connection between the proximal waist 136 and the catheter shaft 122.

In some embodiments, the electrode support 605 is disposed over the expandable member 130 and expands when the expandable member 130 is expanded. The elongate members 610 are free from attachment to the body 135 of the expandable member 130, allowing the elongate members 610 to move farther apart from each other during expansion. The elongate members 610 may be attached to each other at their distal 615 and proximal 620 ends. In some embodiments, the distal ends 615 of the elongate members 610 may be attached to the distal waist 137 of the expandable member 130 and the proximal ends 620 of the elongate members 610 may be attached to proximal waist 136 of the expandable member 130. In other embodiments, the distal 615 and proximal 620 ends of the elongate members 610 may be attached to the catheter shaft 122. The electrode support 605 may include a plurality of electrode assemblies 625 spaced apart axially along the electrode support 605.

In some embodiments, the electrode support 605 includes one or more additional elongate members 611 disposed in a helical or spiral pattern or orientation along an outer surface of the expandable member 130. The additional elongate members 611 may balance the electrode assembly 625. The additional elongate members 611 may be free of electrodes or other elements. In some embodiments, two sets of three additional elongate members 611 may be present. The additional elongate members 611 may be connected to each other only at their proximal and distal ends and may be free of connection to the body 135 of the expandable member 130.

In embodiments utilizing a monopolar electrode, a separate common ground electrode 632 may be used. The common ground electrode 632 may be capable of being a return electrical pathway for the active electrode 635. Thus, energy may be delivered to the active electrode 635 and the common ground electrode may be the return electrical pathway. As the name suggests, the common ground electrode may be utilized as a common ground for more than one active electrode. For example, the ablation device 600 may include a plurality of active electrodes, such as in FIG. 15, and a common ground electrode may be a common ground for at least some or, in at least some embodiments, all of the active electrodes. Various embodiments are contemplated that include any suitable number of active electrodes including one, two, three, four, five, six, seven, eight, nine, ten, or more active electrodes.

Because the common ground electrode may be utilized as the return electrode for a plurality of active electrodes, the active electrodes need not have a bipolar return electrode (i.e., ground trace) paired with each active electrode. This may allow active electrodes and/or the other structures associated therewith to be constructed with a smaller size or footprint. This may desirably impact the overall construction of device. For example, smaller active electrodes may be more flexible, allow for easier contracting or folding of the electrode support when proximally retracting the ablation device, reduce the profile of the ablation device, or the like.

In use, the ablation device 300, 400, 500, 600 may be advanced through a blood vessel to a position adjacent to a target tissue (e.g., within a renal artery). In some embodiments, the target tissue may be one or more renal nerves disposed about the renal artery. When suitably positioned, expandable member 130 may be expanded from a collapsed delivery configuration to an expanded configuration. This may place the active electrode 335, 435, 535, 635 against the wall of the blood vessel. The active electrode 335, 435, 535, 635 may be activated. Ablation energy may be transmitted from the active electrode 335, 435, 535, 635, through the target tissue (where renal nerves may be ablated, modulated, or otherwise impacted), and back through the ground electrode 330, 430, 530, 630, in a bipolar configuration, or back through the common ground electrode 632, in a monopolar configuration.

The materials that can be used for the various components of the ablation device 300, 400, 500, 600 (and/or other devices disclosed herein) may include those commonly associated with medical devices. For simplicity purposes, the following discussion makes reference to the ablation device 300, 400, 500, 600. However, this is not intended to limit the devices and methods described herein, as the discussion may be applied to other similar tubular members and/or expandable members and/or components of tubular members and/or expandable members disclosed herein.

The ablation device 300, 400, 500, 600 and the various components thereof may be made from a metal, metal alloy, polymer (some examples of which are disclosed below), a metal-polymer composite, ceramics, combinations thereof, and the like, or other suitable material. Some examples of suitable polymers may include polytetrafluoroethylene (PTFE), ethylene tetrafluoroethylene (ETFE), fluorinated ethylene propylene (FEP), polyoxymethylene (POM, for example, DELRIN® available from DuPont), polyether block ester, polyurethane (for example, Polyurethane 85A), polypropylene (PP), polyvinylchloride (PVC), polyether-ester (for example, ARNITEL® available from DSM Engineering Plastics), ether or ester based copolymers (for example, butylene/poly(alkylene ether) phthalate and/or other polyester elastomers such as HYTREL® available from DuPont), polyamide (for example, DURETHAN® available from Bayer or CRISTAMID® available from Elf Atochem), elastomeric polyamides, block polyamide/ethers, polyether block amide (PEBA, for example available under the trade name PEBAX®), ethylene vinyl acetate copolymers (EVA), silicones, polyethylene (PE), Marlex high-density polyethylene, Marlex low-density polyethylene, linear low density polyethylene (for example REXELL®), polyester, polybutylene terephthalate (PBT), polyethylene terephthalate (PET), polytrimethylene terephthalate, polyethylene naphthalate (PEN), polyetheretherketone (PEEK), polyimide (PI), polyetherimide (PEI), polyphenylene sulfide (PPS), polyphenylene oxide (PPO), poly paraphenylene terephthalamide (for example, KEVLAR®), polysulfone, nylon, nylon-12 (such as GRILAMID® available from EMS American Grilon), perfluoro(propyl vinyl ether) (PFA), ethylene vinyl alcohol, polyolefin, polystyrene, epoxy, polyvinylidene chloride (PVdC), poly(styrene-b-isobutylene-b-styrene) (for example, SIBS and/or SIBS 50A), polycarbonates, ionomers, biocompatible polymers, other suitable materials, or mixtures, combinations, copolymers thereof, polymer/metal composites, and the like. In some embodiments the sheath can be blended with a liquid crystal polymer (LCP). For example, the mixture can contain up to about 6 percent LCP.

Some examples of suitable metals and metal alloys include stainless steel, such as 304V, 304L, and 316LV stainless steel; mild steel; nickel-titanium alloy such as linear-elastic and/or super-elastic nitinol; other nickel alloys such as nickel-chromium-molybdenum alloys (e.g., UNS: N06625 such as INCONEL® 625, UNS: N06022 such as HASTELLOY® C-22®, UNS: N10276 such as HASTELLOY® C276®, other HASTELLOY® alloys, and the like), nickel-copper alloys (e.g., UNS: N04400 such as MONEL® 400, NICKELVAC® 400, NICORROS® 400, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nickel-molybdenum alloys (e.g., UNS: N10665 such as HASTELLOY® ALLOY B2®), other nickel-chromium alloys, other nickel-molybdenum alloys, other nickel-cobalt alloys, other nickel-iron alloys, other nickel-copper alloys, other nickel-tungsten or tungsten alloys, and the like; cobalt-chromium alloys; cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like); platinum enriched stainless steel; titanium; combinations thereof; and the like; or any other suitable material.

As alluded to herein, within the family of commercially available nickel-titanium or nitinol alloys, is a category designated “linear elastic” or “non-super-elastic” which, although may be similar in chemistry to conventional shape memory and super elastic varieties, may exhibit distinct and useful mechanical properties. Linear elastic and/or non-super-elastic nitinol may be distinguished from super elastic nitinol in that the linear elastic and/or non-super-elastic nitinol does not display a substantial “superelastic plateau” or “flag region” in its stress/strain curve like super elastic nitinol does. Instead, in the linear elastic and/or non-super-elastic nitinol, as recoverable strain increases, the stress continues to increase in a substantially linear, or a somewhat, but not necessarily entirely linear relationship until plastic deformation begins or at least in a relationship that is more linear that the super elastic plateau and/or flag region that may be seen with super elastic nitinol. Thus, for the purposes of this disclosure linear elastic and/or non-super-elastic nitinol may also be termed “substantially” linear elastic and/or non-super-elastic nitinol.

In some cases, linear elastic and/or non-super-elastic nitinol may also be distinguishable from super elastic nitinol in that linear elastic and/or non-super-elastic nitinol may accept up to about 2-5% strain while remaining substantially elastic (e.g., before plastically deforming) whereas super elastic nitinol may accept up to about 8% strain before plastically deforming. Both of these materials can be distinguished from other linear elastic materials such as stainless steel (that can also can be distinguished based on its composition), which may accept only about 0.2 to 0.44 percent strain before plastically deforming.

In some embodiments, the linear elastic and/or non-super-elastic nickel-titanium alloy is an alloy that does not show any martensite/austenite phase changes that are detectable by differential scanning calorimetry (DSC) and dynamic metal thermal analysis (DMTA) analysis over a large temperature range. For example, in some embodiments, there may be no martensite/austenite phase changes detectable by DSC and DMTA analysis in the range of about −60 degrees Celsius (° C.) to about 120° C. in the linear elastic and/or non-super-elastic nickel-titanium alloy. The mechanical bending properties of such material may therefore be generally inert to the effect of temperature over this very broad range of temperature. In some embodiments, the mechanical bending properties of the linear elastic and/or non-super-elastic nickel-titanium alloy at ambient or room temperature are substantially the same as the mechanical properties at body temperature, for example, in that they do not display a super-elastic plateau and/or flag region. In other words, across a broad temperature range, the linear elastic and/or non-super-elastic nickel-titanium alloy maintains its linear elastic and/or non-super-elastic characteristics and/or properties.

In some embodiments, the linear elastic and/or non-super-elastic nickel-titanium alloy may be in the range of about 50 to about 60 weight percent nickel, with the remainder being essentially titanium. In some embodiments, the composition is in the range of about 54 to about 57 weight percent nickel. One example of a suitable nickel-titanium alloy is FHP-NT alloy commercially available from Furukawa Techno Material Co. of Kanagawa, Japan. Some examples of nickel titanium alloys are disclosed in U.S. Pat. Nos. 5,238,004 and 6,508,803, which are incorporated herein by reference. Other suitable materials may include ULTANIUM™ (available from Neo-Metrics) and GUM METAL™ (available from Toyota). In some other embodiments, a superelastic alloy, for example a superelastic nitinol can be used to achieve desired properties.

In at least some embodiments, portions of the ablation device 120 may also be doped with, made of, or otherwise include a radiopaque material. Radiopaque materials are understood to be materials capable of producing a relatively bright image on a fluoroscopy screen or another imaging technique during a medical procedure. This relatively bright image aids the user of the ablation device 120 in determining its location. Some examples of radiopaque materials can include, but are not limited to, gold, platinum, palladium, tantalum, tungsten alloy, polymer material loaded with a radiopaque filler, and the like. Additionally, other radiopaque marker bands and/or coils may also be incorporated into the design of the ablation device 120 to achieve the same result.

In some embodiments, a degree of Magnetic Resonance Imaging (MRI) compatibility may be imparted into the ablation device 120. For example, portions of device, may be made of a material that does not substantially distort the image and create substantial artifacts (i.e., gaps in the image). Certain ferromagnetic materials, for example, may not be suitable because they may create artifacts in an MRI image. In some of these and in other embodiments, portions of the ablation device 120 may also be made from a material that the MRI machine can image. Some materials that exhibit these characteristics include, for example, tungsten, cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nitinol, and the like, and others.

The entire disclosures of the following documents are herein incorporated by reference in their entirety:

U.S. patent application Ser. No. 13/750,879, filed on Jan. 25, 2013, and entitled “METHODS AND APPARATUSES FOR REMODELING TISSUE OF OR ADJACENT TO A BODY PASSAGE”.

It should be understood that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps without exceeding the scope of the disclosure. This may include, to the extent that it is appropriate, the use of any of the features of one example embodiment being used in other embodiments. The invention's scope is, of course, defined in the language in which the appended claims are expressed.

Claims

1. A medical device for nerve ablation, comprising: a catheter shaft;an expandable member coupled to the catheter shaft, the expandable member having a proximal region, a distal region, and a body extending therebetween, the expandable member being a balloon; andan electrode support coupled to the catheter shaft and positioned over the body of the expandable member, the electrode support including a plurality of spaced apart flexible elongate members, each having a distal end, a proximal end, and a body extending therebetween, and a plurality of electrode assemblies disposed on the electrode support, the electrode support capable of expanding with the expandable member, wherein the electrode support is free from attachment with the body of the expandable member and wherein the plurality of spaced apart flexible elongate members are connected to each other at their proximal and distal ends,wherein the plurality of spaced apart flexible elongate members extend in a helix over the body of the expandable member.
2. The medical device of claim 1, wherein each of the plurality of spaced apart flexible elongate members includes at least two of the electrode assemblies in a spaced apart arrangement.
3. The medical device of claim 1, wherein the electrode support includes a proximal section, wherein the electrode support and the expandable member are attached to each other only at the proximal section of the electrode support and the proximal region of the expandable member.
4. The medical device of claim 1, wherein the electrode support includes two or more spaced apart sets of three of the plurality of spaced apart flexible elongate members, wherein each of the spaced apart sets includes a first spaced apart flexible elongate member carrying active electrodes, a second spaced apart flexible elongate member including one or more temperature sensors, and a third spaced apart flexible elongate member carrying ground electrodes.
5. The medical device of claim 1, wherein at least some of the plurality of electrode assemblies include a pair of bipolar electrodes.
6. The medical device of claim 1, wherein at least some of the plurality of electrode assemblies include a temperature sensor.
7. The medical device of claim 6, wherein the temperature sensor is positioned between a bottom surface of one of the plurality of electrode assemblies and an outer surface of the expandable member.
8. The medical device of claim 1, wherein the expandable member includes one or more channels in an outer surface extending from a distal region to a proximal region of the expandable member.
9. The medical device of claim 1, wherein the expandable member is a compliant balloon.
10. The medical device of claim 1, wherein the expandable member is a non-compliant balloon.
11. The medical device of claim 1, wherein the expandable member has one or more channels extending along the body, the one or more channels positioned between the plurality of spaced apart flexible elongate members.
12. A medical device, comprising: a catheter shaft;an expandable balloon having a distal waist, proximal waist, and a body extending therebetween, the proximal waist being coupled to the catheter shaft;a flexible elongate electrode assembly coupled to the catheter shaft and extending in a helix over the body of the expandable balloon, the electrode assembly being free from attachment to the body of the expandable balloon, the elongate electrode assembly comprising a plurality of spaced apart elongate members each having a distal region, a proximal region, and a body extending therebetween;a plurality of electrodes disposed on at least a first one of the plurality of spaced apart elongate members; andone or more elongate supports having a distal region, a proximal region, and a body extending therebetween, the one or more elongate supports extending in a helix over the body of the expandable balloon and spaced apart from the plurality of spaced apart elongate members.
13. The medical device of claim 12, wherein the plurality of spaced apart elongate members include three spaced apart elongate members and wherein the three elongate members are free from attachment to each other along their respective bodies.
14. The medical device of claim 12, wherein the one or more elongate supports are connected to the plurality of spaced apart elongate members only at their distal and proximal regions.
15. The medical device of claim 14, further comprising a first circuitry and a second circuitry connected to the electrode elements, wherein the first circuitry extends proximally along the first one of the plurality of spaced apart elongate members, wherein the second circuitry extends distally along the first one of the plurality of spaced apart elongate members to a first one of the one or more elongate supports, the second circuitry then extending proximally along the first one of the one or more elongate supports.
16. A medical device, comprising: a catheter shaft;an expandable balloon having a distal waist, proximal waist, and a body extending therebetween, the proximal waist being coupled to the catheter shaft;a flexible elongate electrode assembly coupled to the catheter shaft and extending in a helix over the body of the expandable balloon, the electrode assembly free from attachment to the body of the expandable balloon, wherein the elongate electrode assembly includes three spaced apart elongate members each having a distal region, a proximal region, and a body extending therebetween, and wherein the three spaced apart elongate members are free from attachment to each other along their respective bodies;a plurality of electrode elements disposed on the flexible elongate electrode assembly; andone or more elongate supports each having a distal region, a proximal region, and a body extending therebetween, the one or more elongate supports extending in a helix over the body of the expandable balloon and spaced apart from the three spaced apart elongate members, the one or more elongate supports connected to the three spaced apart elongate members only at their distal and proximal regions.
17. The medical device of claim 16, further comprising a first circuitry and a second circuitry connected to the electrode elements, wherein the first circuitry extends proximally along a first one of the three spaced apart elongate members on which at least a portion of the plurality of electrode elements reside, wherein the second circuitry extends distally along the first one of the three spaced apart elongate members on which at least a portion of the plurality of electrode elements reside to a first one of the one or more elongate supports, the second circuitry then extending proximally along the first one of the one or more elongate supports.
18. A method for treating hypertension, the method comprising: advancing a medical device in accordance with claim 1 through a blood vessel to a position within a renal artery;expanding the expandable member, thereby expanding the electrode support;energizing the electrode assemblies;collapsing the expandable member, and thereafter, withdrawing the expandable member and the electrode support into a delivery sheath, thereby collapsing the electrode support.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 U.S.C. § 119 to U.S. Provisional Application Ser. No. 61/838,086, filed Jun. 21, 2013, the entirety of which is incorporated herein by reference.

US Referenced Citations (1503)

Number	Name	Date	Kind
164184	Kiddee	Jun 1875	A
852787	Hoerner	May 1907	A
921973	Gillett et al.	May 1909	A
976733	Gilliland	Nov 1910	A
1167014	O'Brien	Jan 1916	A
2505358	Gusberg et al.	Apr 1950	A
2701559	Cooper	Feb 1955	A
3108593	Glassman	Oct 1963	A
3108594	Glassman	Oct 1963	A
3540431	Mobin	Nov 1970	A
3952747	Kimmell	Apr 1976	A
3996938	Clark, III	Dec 1976	A
4046150	Schwartz et al.	Sep 1977	A
4290427	Chin	Sep 1981	A
4402686	Medel	Sep 1983	A
4483341	Witteles et al.	Nov 1984	A
4531943	Van Tassel et al.	Jul 1985	A
4574804	Kurwa	Mar 1986	A
4587975	Salo et al.	May 1986	A
4649936	Ungar et al.	Mar 1987	A
4682596	Bales et al.	Jul 1987	A
4709698	Johnston et al.	Dec 1987	A
4765331	Petruzzi et al.	Aug 1988	A
4770653	Shturman	Sep 1988	A
4784132	Fox et al.	Nov 1988	A
4784162	Ricks et al.	Nov 1988	A
4785806	Deckelbaum et al.	Nov 1988	A
4788975	Shturman et al.	Dec 1988	A
4790310	Ginsburg et al.	Dec 1988	A
4799479	Spears	Jan 1989	A
4823791	D'Amelio et al.	Apr 1989	A
4830003	Wolff et al.	May 1989	A
4849484	Heard	Jul 1989	A
4862886	Clarke et al.	Sep 1989	A
4887605	Angelsen et al.	Dec 1989	A
4890623	Cook et al.	Jan 1990	A
4920979	Bullara et al.	May 1990	A
4938766	Jarvik	Jul 1990	A
4955377	Lennox et al.	Sep 1990	A
4976711	Parins et al.	Dec 1990	A
5034010	Kittrell et al.	Jul 1991	A
5052402	Bencini et al.	Oct 1991	A
5053033	Clarke et al.	Oct 1991	A
5071424	Reger et al.	Dec 1991	A
5074871	Groshong et al.	Dec 1991	A
5098429	Sterzer et al.	Mar 1992	A
5098431	Rydell	Mar 1992	A
5109859	Jenkins	May 1992	A
5125928	Parins et al.	Jun 1992	A
5129396	Rosen et al.	Jul 1992	A
5139496	Hed	Aug 1992	A
5143836	Hartman et al.	Sep 1992	A
5156610	Reger et al.	Oct 1992	A
5158564	Schnepp-Pesch	Oct 1992	A
5170802	Mehra	Dec 1992	A
5178620	Eggers et al.	Jan 1993	A
5178625	Groshong et al.	Jan 1993	A
5190540	Lee	Mar 1993	A
5211651	Reger et al.	May 1993	A
5234407	Teirstein et al.	Aug 1993	A
5238004	Sahatjian et al.	Aug 1993	A
5242441	Avitall	Sep 1993	A
5251634	Weinberg et al.	Oct 1993	A
5255679	Imran	Oct 1993	A
5263493	Avitall	Nov 1993	A
5267954	Nita et al.	Dec 1993	A
5277201	Stern et al.	Jan 1994	A
5282484	Reger et al.	Feb 1994	A
5286254	Shapland et al.	Feb 1994	A
5290306	Trotta et al.	Mar 1994	A
5295484	Marcus	Mar 1994	A
5297564	Love et al.	Mar 1994	A
5300068	Rosar et al.	Apr 1994	A
5301683	Durkan	Apr 1994	A
5304115	Pflueger et al.	Apr 1994	A
5304121	Sahatjian	Apr 1994	A
5304171	Gregory et al.	Apr 1994	A
5304173	Kittrell et al.	Apr 1994	A
5306250	March et al.	Apr 1994	A
5312328	Nita et al.	May 1994	A
5314466	Stern et al.	May 1994	A
5322064	Lundquist	Jun 1994	A
5324255	Passafaro et al.	Jun 1994	A
5326341	Lew et al.	Jul 1994	A
5326342	Plueger et al.	Jul 1994	A
5330518	Neilson et al.	Jul 1994	A
5333614	Feiring	Aug 1994	A
5342292	Nita et al.	Aug 1994	A
5344395	Whalen et al.	Sep 1994	A
5364392	Warner et al.	Nov 1994	A
5365172	Hrovat et al.	Nov 1994	A
5368557	Nita et al.	Nov 1994	A
5368558	Nita et al.	Nov 1994	A
5380274	Nita et al.	Jan 1995	A
5380319	Saito et al.	Jan 1995	A
5382228	Nita et al.	Jan 1995	A
5383874	Jackson et al.	Jan 1995	A
5383917	Desai et al.	Jan 1995	A
5397301	Pflueger et al.	Mar 1995	A
5397339	Desai	Mar 1995	A
5401272	Perkins et al.	Mar 1995	A
5403311	Abele et al.	Apr 1995	A
5405318	Nita et al.	Apr 1995	A
5405346	Grundy et al.	Apr 1995	A
5409000	Imran	Apr 1995	A
5417672	Nita et al.	May 1995	A
5419767	Eggers et al.	May 1995	A
5427118	Nita et al.	Jun 1995	A
5432876	Appeldorn et al.	Jul 1995	A
5441498	Perkins et al.	Aug 1995	A
5447509	Mills et al.	Sep 1995	A
5451207	Yock et al.	Sep 1995	A
5453091	Taylor et al.	Sep 1995	A
5454788	Walker et al.	Oct 1995	A
5454809	Janssen	Oct 1995	A
5455029	Hartman et al.	Oct 1995	A
5456682	Edwards et al.	Oct 1995	A
5457042	Hartman et al.	Oct 1995	A
5471982	Edwards et al.	Dec 1995	A
5474530	Passafaro et al.	Dec 1995	A
5478351	Meade et al.	Dec 1995	A
5496311	Abele et al.	Mar 1996	A
5496312	Klicek et al.	Mar 1996	A
5498261	Strul	Mar 1996	A
5505201	Grill et al.	Apr 1996	A
5505730	Edwards	Apr 1996	A
5507744	Tay et al.	Apr 1996	A
5512051	Wang et al.	Apr 1996	A
5522873	Jackman et al.	Jun 1996	A
5531520	Grimson et al.	Jul 1996	A
5540656	Pflueger et al.	Jul 1996	A
5540679	Fram et al.	Jul 1996	A
5540681	Strul et al.	Jul 1996	A
5542917	Nita et al.	Aug 1996	A
5545161	Imran	Aug 1996	A
5562100	Kittrell et al.	Oct 1996	A
5571122	Kelly et al.	Nov 1996	A
5571151	Gregory	Nov 1996	A
5573531	Gregory et al.	Nov 1996	A
5573533	Strul	Nov 1996	A
5584831	McKay	Dec 1996	A
5584872	Lafontaine et al.	Dec 1996	A
5588962	Nicholas et al.	Dec 1996	A
5599346	Edwards et al.	Feb 1997	A
5601526	Chapelon et al.	Feb 1997	A
5609606	O'Boyle et al.	Mar 1997	A
5613979	Trotta et al.	Mar 1997	A
5626576	Janssen	May 1997	A
5630837	Crowley	May 1997	A
5637090	McGee et al.	Jun 1997	A
5643255	Organ	Jul 1997	A
5643297	Nordgren et al.	Jul 1997	A
5647847	Lafontaine et al.	Jul 1997	A
5649923	Gregory et al.	Jul 1997	A
5651780	Jackson et al.	Jul 1997	A
5653684	Laptewicz et al.	Aug 1997	A
5662671	Barbut et al.	Sep 1997	A
5665062	Houser	Sep 1997	A
5665098	Kelly et al.	Sep 1997	A
5666964	Meilus	Sep 1997	A
5667490	Keith et al.	Sep 1997	A
5672174	Gough et al.	Sep 1997	A
5676693	Lafontaine	Oct 1997	A
5678296	Fleischhacker et al.	Oct 1997	A
5681282	Eggers et al.	Oct 1997	A
RE35656	Feinberg	Nov 1997	E
5687737	Branham et al.	Nov 1997	A
5688266	Edwards et al.	Nov 1997	A
5693015	Walker et al.	Dec 1997	A
5693029	Leonhardt et al.	Dec 1997	A
5693043	Kittrell et al.	Dec 1997	A
5693082	Warner et al.	Dec 1997	A
5695504	Gifford et al.	Dec 1997	A
5697369	Long, Jr. et al.	Dec 1997	A
5697909	Eggers et al.	Dec 1997	A
5702386	Stern et al.	Dec 1997	A
5702433	Taylor et al.	Dec 1997	A
5706809	Littmann et al.	Jan 1998	A
5713942	Stern et al.	Feb 1998	A
5715819	Svenson et al.	Feb 1998	A
5735846	Panescu et al.	Apr 1998	A
5741214	Ouchi et al.	Apr 1998	A
5741248	Stern et al.	Apr 1998	A
5741249	Moss et al.	Apr 1998	A
5743903	Stern et al.	Apr 1998	A
5748347	Erickson	May 1998	A
5749914	Janssen	May 1998	A
5755682	Knudson et al.	May 1998	A
5755715	Stern et al.	May 1998	A
5755753	Knowlton et al.	May 1998	A
5769847	Panescu et al.	Jun 1998	A
5769880	Truckai et al.	Jun 1998	A
5775338	Hastings	Jul 1998	A
5776174	Van Tassel	Jul 1998	A
5779698	Clayman et al.	Jul 1998	A
5782760	Schaer	Jul 1998	A
5785702	Murphy et al.	Jul 1998	A
5797849	Vesely et al.	Aug 1998	A
5797903	Swanson et al.	Aug 1998	A
5800484	Gough et al.	Sep 1998	A
5800494	Campbell et al.	Sep 1998	A
5807306	Shapland et al.	Sep 1998	A
5810802	Panescu et al.	Sep 1998	A
5810803	Moss et al.	Sep 1998	A
5810810	Tay et al.	Sep 1998	A
5817092	Behl	Oct 1998	A
5817113	Gifford et al.	Oct 1998	A
5817144	Gregory et al.	Oct 1998	A
5823956	Roth et al.	Oct 1998	A
5827203	Nita et al.	Oct 1998	A
5827268	Laufer	Oct 1998	A
5829447	Stevens et al.	Nov 1998	A
5830213	Panescu et al.	Nov 1998	A
5830222	Makower	Nov 1998	A
5832228	Holden et al.	Nov 1998	A
5833593	Liprie	Nov 1998	A
5836874	Swanson et al.	Nov 1998	A
5840076	Swanson et al.	Nov 1998	A
5843016	Lugnani et al.	Dec 1998	A
5846238	Jackson et al.	Dec 1998	A
5846239	Swanson et al.	Dec 1998	A
5846245	McCarthy et al.	Dec 1998	A
5848969	Panescu et al.	Dec 1998	A
5853411	Whayne et al.	Dec 1998	A
5855614	Stevens et al.	Jan 1999	A
5860974	Abele	Jan 1999	A
5865801	Houser	Feb 1999	A
5868735	Lafontaine et al.	Feb 1999	A
5868736	Swanson et al.	Feb 1999	A
5871483	Jackson et al.	Feb 1999	A
5871524	Knowlton et al.	Feb 1999	A
5875782	Ferrari et al.	Mar 1999	A
5876369	Houser	Mar 1999	A
5876374	Alba et al.	Mar 1999	A
5876397	Edelman et al.	Mar 1999	A
5879348	Owens et al.	Mar 1999	A
5891114	Chien et al.	Apr 1999	A
5891135	Jackson et al.	Apr 1999	A
5891136	McGee et al.	Apr 1999	A
5891138	Tu et al.	Apr 1999	A
5895378	Nita	Apr 1999	A
5897552	Edwards et al.	Apr 1999	A
5902328	Lafontaine et al.	May 1999	A
5904651	Swanson et al.	May 1999	A
5904667	Falwell et al.	May 1999	A
5904697	Gifford et al.	May 1999	A
5904709	Arndt et al.	May 1999	A
5906614	Stern et al.	May 1999	A
5906623	Peterson	May 1999	A
5906636	Casscells et al.	May 1999	A
5916192	Nita et al.	Jun 1999	A
5916227	Keith et al.	Jun 1999	A
5916239	Geddes et al.	Jun 1999	A
5919219	Knowlton et al.	Jul 1999	A
5924424	Stevens et al.	Jul 1999	A
5925038	Panescu et al.	Jul 1999	A
5934284	Plaia et al.	Aug 1999	A
5935063	Nguyen	Aug 1999	A
5938670	Keith et al.	Aug 1999	A
5947977	Slepian et al.	Sep 1999	A
5948011	Knowlton et al.	Sep 1999	A
5951494	Wang et al.	Sep 1999	A
5951539	Nita et al.	Sep 1999	A
5954717	Behl et al.	Sep 1999	A
5957882	Nita et al.	Sep 1999	A
5957941	Ream et al.	Sep 1999	A
5957969	Warner et al.	Sep 1999	A
5961513	Swanson et al.	Oct 1999	A
5964757	Ponzi et al.	Oct 1999	A
5967976	Larsen et al.	Oct 1999	A
5967978	Littmann et al.	Oct 1999	A
5967984	Chu et al.	Oct 1999	A
5971975	Mills et al.	Oct 1999	A
5972026	Laufer et al.	Oct 1999	A
5980563	Tu et al.	Nov 1999	A
5989208	Nita et al.	Nov 1999	A
5989284	Laufer	Nov 1999	A
5993462	Pomeranz et al.	Nov 1999	A
5997497	Nita et al.	Dec 1999	A
5999678	Murphy et al.	Dec 1999	A
6004269	Crowley et al.	Dec 1999	A
6004316	Laufer et al.	Dec 1999	A
6007514	Nita	Dec 1999	A
6010522	Barbut et al.	Jan 2000	A
6013033	Berger et al.	Jan 2000	A
6014590	Whayne et al.	Jan 2000	A
6022309	Celliers et al.	Feb 2000	A
6024740	Lesh	Feb 2000	A
6030611	Gorecki et al.	Feb 2000	A
6032675	Rubinsky et al.	Mar 2000	A
6033397	Laufer et al.	Mar 2000	A
6033398	Farley et al.	Mar 2000	A
6036687	Laufer et al.	Mar 2000	A
6036689	Tu et al.	Mar 2000	A
6041260	Stern et al.	Mar 2000	A
6050994	Sherman et al.	Apr 2000	A
6056744	Edwards	May 2000	A
6056746	Goble et al.	May 2000	A
6063085	Tay et al.	May 2000	A
6066096	Smith et al.	May 2000	A
6066139	Ryan et al.	May 2000	A
6068638	Makower	May 2000	A
6068653	Lafontaine	May 2000	A
6071277	Farley et al.	Jun 2000	A
6071278	Panescu et al.	Jun 2000	A
6078839	Carson	Jun 2000	A
6079414	Roth	Jun 2000	A
6080171	Keith et al.	Jun 2000	A
6081749	Ingle et al.	Jun 2000	A
6086581	Reynolds et al.	Jul 2000	A
6091995	Ingle et al.	Jul 2000	A
6093166	Knudson et al.	Jul 2000	A
6096021	Helm et al.	Aug 2000	A
6099526	Whayne et al.	Aug 2000	A
6102908	Tu et al.	Aug 2000	A
6106477	Miesel et al.	Aug 2000	A
6110187	Donlon et al.	Aug 2000	A
6110192	Ravenscroft et al.	Aug 2000	A
6114311	Parmacek et al.	Sep 2000	A
6117101	Diederich et al.	Sep 2000	A
6117128	Gregory	Sep 2000	A
6120476	Fung et al.	Sep 2000	A
6120516	Selmon et al.	Sep 2000	A
6121775	Pearlman	Sep 2000	A
6123679	Lafaut et al.	Sep 2000	A
6123682	Knudson et al.	Sep 2000	A
6123702	Swanson et al.	Sep 2000	A
6123703	Tu et al.	Sep 2000	A
6123718	Tu et al.	Sep 2000	A
6129725	Tu et al.	Oct 2000	A
6135997	Laufer et al.	Oct 2000	A
6142991	Schatzberger et al.	Nov 2000	A
6142993	Whayne et al.	Nov 2000	A
6149647	Tu et al.	Nov 2000	A
6152899	Farley et al.	Nov 2000	A
6152912	Jansen et al.	Nov 2000	A
6156046	Passafaro et al.	Dec 2000	A
6158250	Tibbals et al.	Dec 2000	A
6159187	Park et al.	Dec 2000	A
6159225	Makower	Dec 2000	A
6161048	Sluijter et al.	Dec 2000	A
6162184	Swanson et al.	Dec 2000	A
6165163	Chien et al.	Dec 2000	A
6165172	Farley et al.	Dec 2000	A
6165187	Reger et al.	Dec 2000	A
6168594	Lafontaine et al.	Jan 2001	B1
6171321	Gifford, III et al.	Jan 2001	B1
6179832	Jones et al.	Jan 2001	B1
6179835	Panescu et al.	Jan 2001	B1
6179859	Bates et al.	Jan 2001	B1
6183468	Swanson et al.	Feb 2001	B1
6183486	Snow et al.	Feb 2001	B1
6190379	Heuser et al.	Feb 2001	B1
6191862	Swanson et al.	Feb 2001	B1
6197021	Panescu et al.	Mar 2001	B1
6200266	Shokrollahi et al.	Mar 2001	B1
6203537	Adrian	Mar 2001	B1
6203561	Ramee et al.	Mar 2001	B1
6210406	Webster	Apr 2001	B1
6211247	Goodman	Apr 2001	B1
6217576	Tu et al.	Apr 2001	B1
6219577	Brown, III et al.	Apr 2001	B1
6228076	Winston et al.	May 2001	B1
6228109	Tu et al.	May 2001	B1
6231516	Keilman et al.	May 2001	B1
6231587	Makower	May 2001	B1
6235044	Root et al.	May 2001	B1
6236883	Ciaccio et al.	May 2001	B1
6237605	Vaska et al.	May 2001	B1
6238389	Paddock et al.	May 2001	B1
6238392	Long	May 2001	B1
6241666	Pomeranz et al.	Jun 2001	B1
6241753	Knowlton	Jun 2001	B1
6245020	Moore et al.	Jun 2001	B1
6245045	Stratienko	Jun 2001	B1
6248126	Lesser et al.	Jun 2001	B1
6251128	Knopp et al.	Jun 2001	B1
6258087	Edwards et al.	Jul 2001	B1
6273886	Edwards et al.	Aug 2001	B1
6280466	Kugler et al.	Aug 2001	B1
6283935	Laufer et al.	Sep 2001	B1
6283959	Lalonde et al.	Sep 2001	B1
6284743	Parmacek et al.	Sep 2001	B1
6287323	Hammerslag	Sep 2001	B1
6290696	Lafontaine	Sep 2001	B1
6292695	Webster, Jr. et al.	Sep 2001	B1
6293942	Goble et al.	Sep 2001	B1
6293943	Panescu et al.	Sep 2001	B1
6296619	Brisken et al.	Oct 2001	B1
6298256	Meyer	Oct 2001	B1
6299379	Lewis	Oct 2001	B1
6299623	Wulfman	Oct 2001	B1
6309379	Willard et al.	Oct 2001	B1
6309399	Barbut et al.	Oct 2001	B1
6311090	Knowlton	Oct 2001	B1
6317615	KenKnight et al.	Nov 2001	B1
6319242	Patterson et al.	Nov 2001	B1
6319251	Tu et al.	Nov 2001	B1
6322559	Daulton et al.	Nov 2001	B1
6325797	Stewart et al.	Dec 2001	B1
6325799	Goble	Dec 2001	B1
6328699	Eigler et al.	Dec 2001	B1
6346074	Roth	Feb 2002	B1
6346104	Daly et al.	Feb 2002	B2
6350248	Knudson et al.	Feb 2002	B1
6350276	Knowlton	Feb 2002	B1
6353751	Swanson et al.	Mar 2002	B1
6355029	Joye et al.	Mar 2002	B1
6357447	Swanson et al.	Mar 2002	B1
6361519	Knudson et al.	Mar 2002	B1
6364840	Crowley	Apr 2002	B1
6371965	Gifford, III et al.	Apr 2002	B2
6375668	Gifford et al.	Apr 2002	B1
6377854	Knowlton	Apr 2002	B1
6377855	Knowlton	Apr 2002	B1
6379352	Reynolds et al.	Apr 2002	B1
6379373	Sawhney et al.	Apr 2002	B1
6381497	Knowlton	Apr 2002	B1
6381498	Knowlton	Apr 2002	B1
6383151	Diederich et al.	May 2002	B1
6387105	Gifford, III et al.	May 2002	B1
6387380	Knowlton	May 2002	B1
6389311	Whayne et al.	May 2002	B1
6389314	Feiring	May 2002	B2
6391024	Sun et al.	May 2002	B1
6394096	Constantz	May 2002	B1
6394956	Chandrasekaran et al.	May 2002	B1
6398780	Farley et al.	Jun 2002	B1
6398782	Pecor et al.	Jun 2002	B1
6398792	O'Connor	Jun 2002	B1
6401720	Stevens et al.	Jun 2002	B1
6402719	Ponzi et al.	Jun 2002	B1
6405090	Knowlton	Jun 2002	B1
6409723	Edwards	Jun 2002	B1
6413255	Stern	Jul 2002	B1
6421559	Pearlman	Jul 2002	B1
6423057	He et al.	Jul 2002	B1
6425867	Vaezy et al.	Jul 2002	B1
6425912	Knowlton	Jul 2002	B1
6427118	Suzuki	Jul 2002	B1
6428534	Joye et al.	Aug 2002	B1
6428536	Panescu et al.	Aug 2002	B2
6430446	Knowlton	Aug 2002	B1
6432102	Joye et al.	Aug 2002	B2
6436056	Wang et al.	Aug 2002	B1
6438424	Knowlton	Aug 2002	B1
6440125	Rentrop	Aug 2002	B1
6442413	Silver	Aug 2002	B1
6443965	Gifford, III et al.	Sep 2002	B1
6445939	Swanson et al.	Sep 2002	B1
6447505	McGovern et al.	Sep 2002	B2
6447509	Bonnet et al.	Sep 2002	B1
6451034	Gifford, III et al.	Sep 2002	B1
6451044	Naghavi et al.	Sep 2002	B1
6453202	Knowlton	Sep 2002	B1
6454737	Nita et al.	Sep 2002	B1
6454757	Nita et al.	Sep 2002	B1
6454775	Demarais et al.	Sep 2002	B1
6458098	Kanesaka	Oct 2002	B1
6461378	Knowlton	Oct 2002	B1
6468276	McKay	Oct 2002	B1
6468297	Williams et al.	Oct 2002	B1
6470216	Knowlton	Oct 2002	B1
6470219	Edwards et al.	Oct 2002	B1
6471696	Berube et al.	Oct 2002	B1
6475213	Whayne et al.	Nov 2002	B1
6475215	Tanrisever	Nov 2002	B1
6475238	Fedida et al.	Nov 2002	B1
6477426	Fenn et al.	Nov 2002	B1
6480745	Nelson et al.	Nov 2002	B2
6481704	Koster et al.	Nov 2002	B1
6482202	Goble et al.	Nov 2002	B1
6484052	Visuri et al.	Nov 2002	B1
6485489	Teirstein et al.	Nov 2002	B2
6488679	Swanson et al.	Dec 2002	B1
6489307	Phillips et al.	Dec 2002	B1
6491705	Gifford, III et al.	Dec 2002	B2
6494891	Cornish et al.	Dec 2002	B1
6497711	Plaia et al.	Dec 2002	B1
6500172	Panescu et al.	Dec 2002	B1
6500174	Maguire et al.	Dec 2002	B1
6508765	Suorsa et al.	Jan 2003	B2
6508803	Horikawa et al.	Jan 2003	B1
6508804	Sarge et al.	Jan 2003	B2
6508815	Strul et al.	Jan 2003	B1
6511478	Burnside et al.	Jan 2003	B1
6511496	Huter et al.	Jan 2003	B1
6511500	Rahme	Jan 2003	B1
6514236	Stratienko	Feb 2003	B1
6514245	Williams et al.	Feb 2003	B1
6514248	Eggers et al.	Feb 2003	B1
6517534	McGovern et al.	Feb 2003	B1
6517572	Kugler et al.	Feb 2003	B2
6522913	Swanson et al.	Feb 2003	B2
6522926	Kieval et al.	Feb 2003	B1
6524299	Tran et al.	Feb 2003	B1
6527765	Kelman et al.	Mar 2003	B2
6527769	Langberg et al.	Mar 2003	B2
6540761	Houser	Apr 2003	B2
6542781	Koblish et al.	Apr 2003	B1
6544780	Wang	Apr 2003	B1
6546272	MacKinnon et al.	Apr 2003	B1
6547788	Maguire et al.	Apr 2003	B1
6549800	Atalar et al.	Apr 2003	B1
6552796	Magnin et al.	Apr 2003	B2
6554780	Sampson et al.	Apr 2003	B1
6558381	Ingle et al.	May 2003	B2
6558382	Jahns et al.	May 2003	B2
6564096	Mest	May 2003	B2
6565582	Gifford, III et al.	May 2003	B2
6569109	Sakurai et al.	May 2003	B2
6569177	Dillard et al.	May 2003	B1
6570659	Schmitt	May 2003	B2
6572551	Smith et al.	Jun 2003	B1
6572612	Stewart et al.	Jun 2003	B2
6577902	Laufer et al.	Jun 2003	B1
6579308	Jansen et al.	Jun 2003	B1
6579311	Makower	Jun 2003	B1
6582423	Thapliyal et al.	Jun 2003	B1
6589238	Edwards et al.	Jul 2003	B2
6592526	Lenker	Jul 2003	B1
6592567	Levin et al.	Jul 2003	B1
6595959	Stratienko	Jul 2003	B1
6600956	Maschino et al.	Jul 2003	B2
6602242	Fung	Aug 2003	B1
6602246	Joye et al.	Aug 2003	B1
6605056	Eidenschink et al.	Aug 2003	B2
6605084	Acker et al.	Aug 2003	B2
6623452	Chien et al.	Sep 2003	B2
6623453	Guibert et al.	Sep 2003	B1
6632193	Davison et al.	Oct 2003	B1
6632196	Houser	Oct 2003	B1
6645223	Boyle et al.	Nov 2003	B2
6648854	Patterson et al.	Nov 2003	B1
6648878	Lafontaine	Nov 2003	B2
6648879	Joye et al.	Nov 2003	B2
6651672	Roth	Nov 2003	B2
6652513	Panescu et al.	Nov 2003	B2
6652515	Maguire et al.	Nov 2003	B1
6656136	Weng et al.	Dec 2003	B1
6658279	Swanson et al.	Dec 2003	B2
6659981	Stewart et al.	Dec 2003	B2
6666858	Lafontaine	Dec 2003	B2
6666863	Wentzel et al.	Dec 2003	B2
6669655	Acker et al.	Dec 2003	B1
6669692	Nelson et al.	Dec 2003	B1
6673040	Samson et al.	Jan 2004	B1
6673064	Rentrop	Jan 2004	B1
6673066	Werneth	Jan 2004	B2
6673090	Root et al.	Jan 2004	B2
6673101	Fitzgerald et al.	Jan 2004	B1
6673290	Whayne et al.	Jan 2004	B1
6676678	Gifford, III et al.	Jan 2004	B2
6679268	Stevens et al.	Jan 2004	B2
6681773	Murphy et al.	Jan 2004	B2
6682541	Gifford, III et al.	Jan 2004	B1
6684098	Oshio et al.	Jan 2004	B2
6685732	Kramer	Feb 2004	B2
6685733	Dae et al.	Feb 2004	B1
6689086	Nita et al.	Feb 2004	B1
6689148	Sawhney et al.	Feb 2004	B2
6690181	Dowdeswell et al.	Feb 2004	B1
6692490	Edwards	Feb 2004	B1
6695830	Vigil et al.	Feb 2004	B2
6695857	Gifford, III et al.	Feb 2004	B2
6699241	Rappaport et al.	Mar 2004	B2
6699257	Gifford, III et al.	Mar 2004	B2
6702748	Nita et al.	Mar 2004	B1
6702811	Stewart et al.	Mar 2004	B2
6706010	Miki et al.	Mar 2004	B1
6706011	Murphy-Chutorian et al.	Mar 2004	B1
6706037	Zvuloni et al.	Mar 2004	B2
6709431	Lafontaine	Mar 2004	B2
6711429	Gilboa et al.	Mar 2004	B1
6712815	Sampson et al.	Mar 2004	B2
6714822	King et al.	Mar 2004	B2
6716184	Vaezy et al.	Apr 2004	B2
6720350	Kunz et al.	Apr 2004	B2
6723043	Kleeman et al.	Apr 2004	B2
6723064	Babaev	Apr 2004	B2
6736811	Panescu et al.	May 2004	B2
6743184	Sampson et al.	Jun 2004	B2
6746401	Panescu	Jun 2004	B2
6746464	Makower	Jun 2004	B1
6746474	Saadat	Jun 2004	B2
6748953	Sherry et al.	Jun 2004	B2
6749607	Edwards et al.	Jun 2004	B2
6752805	Maguire et al.	Jun 2004	B2
6760616	Hoey et al.	Jul 2004	B2
6763261	Casscells, III et al.	Jul 2004	B2
6764501	Ganz	Jul 2004	B2
6769433	Zikorus et al.	Aug 2004	B2
6770070	Balbierz	Aug 2004	B1
6771996	Bowe et al.	Aug 2004	B2
6773433	Stewart et al.	Aug 2004	B2
6786900	Joye et al.	Sep 2004	B2
6786901	Joye et al.	Sep 2004	B2
6786904	Döscher et al.	Sep 2004	B2
6788977	Fenn et al.	Sep 2004	B2
6790206	Panescu	Sep 2004	B2
6790222	Kugler et al.	Sep 2004	B2
6796981	Wham et al.	Sep 2004	B2
6797933	Mendis et al.	Sep 2004	B1
6797960	Spartiotis et al.	Sep 2004	B1
6800075	Mische et al.	Oct 2004	B2
6802857	Walsh et al.	Oct 2004	B1
6807444	Tu et al.	Oct 2004	B2
6811550	Holland et al.	Nov 2004	B2
6813520	Truckai et al.	Nov 2004	B2
6814730	Li	Nov 2004	B2
6814733	Schwartz et al.	Nov 2004	B2
6823205	Jara	Nov 2004	B1
6824516	Batten et al.	Nov 2004	B2
6827726	Parodi	Dec 2004	B2
6827926	Robinson et al.	Dec 2004	B2
6829497	Mogul	Dec 2004	B2
6830568	Kesten et al.	Dec 2004	B1
6837886	Collins et al.	Jan 2005	B2
6837888	Ciarrocca et al.	Jan 2005	B2
6845267	Harrison et al.	Jan 2005	B2
6847848	Sterzer	Jan 2005	B2
6849073	Hoey et al.	Feb 2005	B2
6849075	Bertolero et al.	Feb 2005	B2
6853425	Kim et al.	Feb 2005	B2
6855123	Nita	Feb 2005	B2
6855143	Davison	Feb 2005	B2
6869431	Maguire et al.	Mar 2005	B2
6872183	Sampson et al.	Mar 2005	B2
6884260	Kugler et al.	Apr 2005	B2
6889694	Hooven	May 2005	B2
6893436	Woodard et al.	May 2005	B2
6895077	Karellas et al.	May 2005	B2
6895265	Silver	May 2005	B2
6898454	Atalar et al.	May 2005	B2
6899711	Stewart et al.	May 2005	B2
6899718	Gifford, III et al.	May 2005	B2
6905494	Yon et al.	Jun 2005	B2
6908462	Joye et al.	Jun 2005	B2
6909009	Koridze	Jun 2005	B2
6911026	Hall et al.	Jun 2005	B1
6915806	Pacek et al.	Jul 2005	B2
6923805	LaFontaine et al.	Aug 2005	B1
6923808	Taimisto	Aug 2005	B2
6926246	Ginggen	Aug 2005	B2
6926713	Rioux et al.	Aug 2005	B2
6926716	Baker et al.	Aug 2005	B2
6929009	Makower et al.	Aug 2005	B2
6929632	Nita et al.	Aug 2005	B2
6929639	Lafontaine	Aug 2005	B2
6932776	Carr	Aug 2005	B2
6936047	Nasab et al.	Aug 2005	B2
6942620	Nita et al.	Sep 2005	B2
6942657	Sinofsky et al.	Sep 2005	B2
6942677	Nita et al.	Sep 2005	B2
6942692	Landau et al.	Sep 2005	B2
6949097	Stewart et al.	Sep 2005	B2
6949121	Laguna	Sep 2005	B1
6952615	Satake	Oct 2005	B2
6953425	Brister	Oct 2005	B2
6955174	Joye et al.	Oct 2005	B2
6955175	Stevens et al.	Oct 2005	B2
6959711	Murphy et al.	Nov 2005	B2
6960207	Vanney et al.	Nov 2005	B2
6962584	Stone et al.	Nov 2005	B1
6964660	Maguire et al.	Nov 2005	B2
6966908	Maguire et al.	Nov 2005	B2
6972015	Joye et al.	Dec 2005	B2
6972024	Kilpatrick et al.	Dec 2005	B1
6974456	Edwards et al.	Dec 2005	B2
6978174	Gelfand et al.	Dec 2005	B2
6979329	Burnside et al.	Dec 2005	B2
6979420	Weber	Dec 2005	B2
6984238	Gifford, III et al.	Jan 2006	B2
6985774	Kieval et al.	Jan 2006	B2
6986739	Warren et al.	Jan 2006	B2
6989009	Lafontaine	Jan 2006	B2
6989010	Francischelli et al.	Jan 2006	B2
6991617	Hektner et al.	Jan 2006	B2
7001378	Yon et al.	Feb 2006	B2
7006858	Silver et al.	Feb 2006	B2
7022105	Edwards	Apr 2006	B1
7022120	Lafontaine	Apr 2006	B2
7025767	Schaefer et al.	Apr 2006	B2
7033322	Silver	Apr 2006	B2
7033372	Cahalan	Apr 2006	B1
7041098	Farley et al.	May 2006	B2
7050848	Hoey et al.	May 2006	B2
7063670	Sampson et al.	Jun 2006	B2
7063679	Maguire et al.	Jun 2006	B2
7063719	Jansen et al.	Jun 2006	B2
7066895	Podany	Jun 2006	B2
7066900	Botto et al.	Jun 2006	B2
7066904	Rosenthal et al.	Jun 2006	B2
7072720	Puskas	Jul 2006	B2
7074217	Strul et al.	Jul 2006	B2
7081112	Joye et al.	Jul 2006	B2
7081114	Rashidi	Jul 2006	B2
7083614	Fjield et al.	Aug 2006	B2
7084276	Vu et al.	Aug 2006	B2
7087026	Callister et al.	Aug 2006	B2
7087051	Bourne et al.	Aug 2006	B2
7087052	Sampson et al.	Aug 2006	B2
7087053	Vanney	Aug 2006	B2
7089065	Westlund et al.	Aug 2006	B2
7097641	Arless et al.	Aug 2006	B1
7100614	Stevens et al.	Sep 2006	B2
7101368	Lafontaine	Sep 2006	B2
7104983	Grasso, III et al.	Sep 2006	B2
7104987	Biggs et al.	Sep 2006	B2
7108715	Lawrence-Brown et al.	Sep 2006	B2
7112196	Brosch et al.	Sep 2006	B2
7112198	Satake	Sep 2006	B2
7112211	Gifford, III et al.	Sep 2006	B2
7122019	Kesten et al.	Oct 2006	B1
7122033	Wood	Oct 2006	B2
7134438	Makower et al.	Nov 2006	B2
7137963	Nita et al.	Nov 2006	B2
7137980	Buysse et al.	Nov 2006	B2
7153315	Miller	Dec 2006	B2
7155271	Halperin et al.	Dec 2006	B2
7157491	Mewshaw et al.	Jan 2007	B2
7157492	Mewshaw et al.	Jan 2007	B2
7158832	Kieval et al.	Jan 2007	B2
7160296	Pearson et al.	Jan 2007	B2
7162303	Levin et al.	Jan 2007	B2
7165551	Edwards et al.	Jan 2007	B2
7169144	Hoey et al.	Jan 2007	B2
7172589	Lafontaine	Feb 2007	B2
7172610	Heitzmann et al.	Feb 2007	B2
7181261	Silver et al.	Feb 2007	B2
7184811	Phan et al.	Feb 2007	B2
7184827	Edwards	Feb 2007	B1
7189227	Lafontaine	Mar 2007	B2
7192427	Chapelon et al.	Mar 2007	B2
7192586	Bander	Mar 2007	B2
7197354	Sobe	Mar 2007	B2
7198632	Lim et al.	Apr 2007	B2
7200445	Dalbec et al.	Apr 2007	B1
7201749	Govari et al.	Apr 2007	B2
7203537	Mower	Apr 2007	B2
7214234	Rapacki et al.	May 2007	B2
7220233	Nita et al.	May 2007	B2
7220239	Wilson et al.	May 2007	B2
7220257	Lafontaine	May 2007	B1
7220270	Sawhney et al.	May 2007	B2
7232458	Saadat	Jun 2007	B2
7232459	Greenberg et al.	Jun 2007	B2
7238184	Megerman et al.	Jul 2007	B2
7241273	Maguire et al.	Jul 2007	B2
7241736	Hunter et al.	Jul 2007	B2
7247141	Makin et al.	Jul 2007	B2
7250041	Chiu et al.	Jul 2007	B2
7250440	Mewshaw et al.	Jul 2007	B2
7252664	Nasab et al.	Aug 2007	B2
7252679	Fischell et al.	Aug 2007	B2
7264619	Venturelli	Sep 2007	B2
7279600	Mewshaw et al.	Oct 2007	B2
7280863	Shachar	Oct 2007	B2
7282213	Schroeder et al.	Oct 2007	B2
7285119	Stewart et al.	Oct 2007	B2
7285120	Im et al.	Oct 2007	B2
7288089	Yon et al.	Oct 2007	B2
7288096	Chin	Oct 2007	B2
7291146	Steinke et al.	Nov 2007	B2
7293562	Malecki et al.	Nov 2007	B2
7294125	Phalen et al.	Nov 2007	B2
7294126	Sampson et al.	Nov 2007	B2
7294127	Leung et al.	Nov 2007	B2
7297131	Nita	Nov 2007	B2
7297475	Koiwai et al.	Nov 2007	B2
7300433	Lane et al.	Nov 2007	B2
7301108	Egitto et al.	Nov 2007	B2
7310150	Guillermo et al.	Dec 2007	B2
7313430	Urquhart et al.	Dec 2007	B2
7314480	Eidenschink et al.	Jan 2008	B2
7314483	Landau et al.	Jan 2008	B2
7317077	Averback et al.	Jan 2008	B2
7323006	Andreas et al.	Jan 2008	B2
7326206	Paul et al.	Feb 2008	B2
7326226	Root et al.	Feb 2008	B2
7326235	Edwards	Feb 2008	B2
7326237	DePalma et al.	Feb 2008	B2
7329236	Kesten et al.	Feb 2008	B2
7335180	Nita et al.	Feb 2008	B2
7335192	Keren et al.	Feb 2008	B2
7338467	Lutter	Mar 2008	B2
7341570	Keren et al.	Mar 2008	B2
7343195	Strommer et al.	Mar 2008	B2
7347857	Anderson et al.	Mar 2008	B2
7348003	Salcedo et al.	Mar 2008	B2
7352593	Zeng et al.	Apr 2008	B2
7354927	Vu	Apr 2008	B2
7359732	Kim et al.	Apr 2008	B2
7361341	Salcedo et al.	Apr 2008	B2
7364566	Elkins et al.	Apr 2008	B2
7367970	Govari et al.	May 2008	B2
7367975	Malecki et al.	May 2008	B2
7371231	Rioux et al.	May 2008	B2
7387126	Cox et al.	Jun 2008	B2
7393338	Nita	Jul 2008	B2
7396355	Goldman et al.	Jul 2008	B2
7402151	Rosenman et al.	Jul 2008	B2
7402312	Rosen et al.	Jul 2008	B2
7404824	Webler et al.	Jul 2008	B1
7406970	Zikorus et al.	Aug 2008	B2
7407502	Strul et al.	Aug 2008	B2
7407506	Makower	Aug 2008	B2
7407671	McBride et al.	Aug 2008	B2
7408021	Averback et al.	Aug 2008	B2
7410486	Fuimaono et al.	Aug 2008	B2
7413556	Zhang et al.	Aug 2008	B2
7425212	Danek et al.	Sep 2008	B1
7426409	Casscells, III et al.	Sep 2008	B2
7435248	Taimisto et al.	Oct 2008	B2
7447453	Kim et al.	Nov 2008	B2
7449018	Kramer	Nov 2008	B2
7452538	Ni et al.	Nov 2008	B2
7473890	Grier et al.	Jan 2009	B2
7476384	Ni et al.	Jan 2009	B2
7479157	Weber et al.	Jan 2009	B2
7481803	Kesten et al.	Jan 2009	B2
7485104	Kieval	Feb 2009	B2
7486805	Krattiger	Feb 2009	B2
7487780	Hooven	Feb 2009	B2
7493154	Bonner et al.	Feb 2009	B2
7494485	Beck et al.	Feb 2009	B2
7494486	Mische et al.	Feb 2009	B2
7494488	Weber	Feb 2009	B2
7494661	Sanders	Feb 2009	B2
7495439	Wiggins	Feb 2009	B2
7497858	Chapelon et al.	Mar 2009	B2
7499745	Littrup et al.	Mar 2009	B2
7500985	Saadat	Mar 2009	B2
7505812	Eggers et al.	Mar 2009	B1
7505816	Schmeling et al.	Mar 2009	B2
7507233	Littrup et al.	Mar 2009	B2
7507235	Keogh et al.	Mar 2009	B2
7511494	Wedeen	Mar 2009	B2
7512445	Truckai et al.	Mar 2009	B2
7527643	Case et al.	May 2009	B2
7529589	Williams et al.	May 2009	B2
7540852	Nita et al.	Jun 2009	B2
7540870	Babaev	Jun 2009	B2
RE40863	Tay et al.	Jul 2009	E
7556624	Laufer et al.	Jul 2009	B2
7558625	Levin et al.	Jul 2009	B2
7563247	Maguire et al.	Jul 2009	B2
7566319	McAuley et al.	Jul 2009	B2
7569052	Phan et al.	Aug 2009	B2
7582111	Krolik et al.	Sep 2009	B2
7584004	Caparso et al.	Sep 2009	B2
7585835	Hill et al.	Sep 2009	B2
7591996	Hwang et al.	Sep 2009	B2
7597704	Frazier et al.	Oct 2009	B2
7598228	Hattori et al.	Oct 2009	B2
7599730	Hunter et al.	Oct 2009	B2
7603166	Casscells, III et al.	Oct 2009	B2
7604608	Nita et al.	Oct 2009	B2
7604633	Truckai et al.	Oct 2009	B2
7615015	Coleman	Nov 2009	B2
7615072	Rust et al.	Nov 2009	B2
7617005	Demarais et al.	Nov 2009	B2
7620451	Demarais et al.	Nov 2009	B2
7621902	Nita et al.	Nov 2009	B2
7621929	Nita et al.	Nov 2009	B2
7626015	Feinstein et al.	Dec 2009	B2
7626235	Kinoshita	Dec 2009	B2
7632268	Edwards et al.	Dec 2009	B2
7632845	Vu et al.	Dec 2009	B2
7635383	Gumm	Dec 2009	B2
7640046	Pastore et al.	Dec 2009	B2
7641633	Laufer et al.	Jan 2010	B2
7641679	Joye et al.	Jan 2010	B2
7646544	Batchko et al.	Jan 2010	B2
7647115	Levin et al.	Jan 2010	B2
7653438	Deem et al.	Jan 2010	B2
7655006	Sauvageau et al.	Feb 2010	B2
7662114	Seip et al.	Feb 2010	B2
7664548	Amurthur et al.	Feb 2010	B2
7670279	Gertner	Mar 2010	B2
7670335	Keidar	Mar 2010	B2
7671084	Mewshaw et al.	Mar 2010	B2
7678104	Keidar	Mar 2010	B2
7678106	Lee	Mar 2010	B2
7678108	Chrisitian et al.	Mar 2010	B2
7686841	Eidenschink et al.	Mar 2010	B2
7691080	Seward et al.	Apr 2010	B2
7699809	Urmey	Apr 2010	B2
7706882	Francischelli et al.	Apr 2010	B2
7715912	Rezai et al.	May 2010	B2
7717853	Nita	May 2010	B2
7717909	Strul et al.	May 2010	B2
7717948	Demarais et al.	May 2010	B2
7722539	Carter et al.	May 2010	B2
7725157	Dumoulin et al.	May 2010	B2
7727178	Wilson et al.	Jun 2010	B2
7736317	Stephens et al.	Jun 2010	B2
7736360	Mody et al.	Jun 2010	B2
7736362	Eberl et al.	Jun 2010	B2
7738952	Yun et al.	Jun 2010	B2
7740629	Anderson et al.	Jun 2010	B2
7741299	Feinstein et al.	Jun 2010	B2
7742795	Stone et al.	Jun 2010	B2
7744594	Yamazaki et al.	Jun 2010	B2
7753907	DiMatteo et al.	Jul 2010	B2
7756583	Demarais et al.	Jul 2010	B2
7758510	Nita et al.	Jul 2010	B2
7758520	Griffin et al.	Jul 2010	B2
7759315	Cuzzocrea et al.	Jul 2010	B2
7766833	Lee et al.	Aug 2010	B2
7766878	Tremaglio, Jr. et al.	Aug 2010	B2
7766892	Keren et al.	Aug 2010	B2
7767844	Lee et al.	Aug 2010	B2
7769427	Shachar	Aug 2010	B2
7771372	Wilson	Aug 2010	B2
7771421	Stewart et al.	Aug 2010	B2
7776967	Perry et al.	Aug 2010	B2
7777486	Hargreaves et al.	Aug 2010	B2
7780660	Bourne et al.	Aug 2010	B2
7789876	Zikorus et al.	Sep 2010	B2
7792568	Zhong et al.	Sep 2010	B2
7799021	Leung et al.	Sep 2010	B2
7803168	Gifford et al.	Sep 2010	B2
7806871	Li et al.	Oct 2010	B2
7811265	Hering et al.	Oct 2010	B2
7811281	Rentrop	Oct 2010	B1
7811313	Mon et al.	Oct 2010	B2
7816511	Kawashima et al.	Oct 2010	B2
7818053	Kassab	Oct 2010	B2
7819866	Bednarek	Oct 2010	B2
7822460	Halperin et al.	Oct 2010	B2
7828837	Khoury	Nov 2010	B2
7832407	Gertner	Nov 2010	B2
7833220	Mon et al.	Nov 2010	B2
7837676	Sinelnikov et al.	Nov 2010	B2
7837720	Mon	Nov 2010	B2
7841978	Gertner	Nov 2010	B2
7846157	Kozel	Dec 2010	B2
7846160	Payne et al.	Dec 2010	B2
7846172	Makower	Dec 2010	B2
7849860	Makower et al.	Dec 2010	B2
7850685	Kunis et al.	Dec 2010	B2
7853333	Demarais	Dec 2010	B2
7854734	Biggs et al.	Dec 2010	B2
7857756	Warren et al.	Dec 2010	B2
7862565	Eder et al.	Jan 2011	B2
7863897	Slocum, Jr. et al.	Jan 2011	B2
7869854	Shachar et al.	Jan 2011	B2
7873417	Demarais et al.	Jan 2011	B2
7887538	Bleich et al.	Feb 2011	B2
7894905	Pless et al.	Feb 2011	B2
7896873	Hiller et al.	Mar 2011	B2
7901400	Wham et al.	Mar 2011	B2
7901402	Jones et al.	Mar 2011	B2
7901420	Dunn	Mar 2011	B2
7905862	Sampson	Mar 2011	B2
7918850	Govari et al.	Apr 2011	B2
7927370	Webler et al.	Apr 2011	B2
7937143	Demarais et al.	May 2011	B2
7938830	Saadat et al.	May 2011	B2
7942874	Eder et al.	May 2011	B2
7942928	Webler et al.	May 2011	B2
7946976	Gertner	May 2011	B2
7950397	Thapliyal et al.	May 2011	B2
7955293	Nita et al.	Jun 2011	B2
7956613	Wald	Jun 2011	B2
7959627	Utley et al.	Jun 2011	B2
7962854	Vance et al.	Jun 2011	B2
7967782	Laufer et al.	Jun 2011	B2
7967808	Fitzgerald et al.	Jun 2011	B2
7972327	Eberl et al.	Jul 2011	B2
7972330	Alejandro et al.	Jul 2011	B2
7983751	Zdeblick et al.	Jul 2011	B2
8001976	Gertner	Aug 2011	B2
8007440	Magnin et al.	Aug 2011	B2
8012147	Lafontaine	Sep 2011	B2
8019435	Hastings et al.	Sep 2011	B2
8021362	Deem et al.	Sep 2011	B2
8021413	Dierking et al.	Sep 2011	B2
8025661	Arnold et al.	Sep 2011	B2
8027718	Spinner et al.	Sep 2011	B2
8031927	Karl et al.	Oct 2011	B2
8033284	Porter et al.	Oct 2011	B2
8043673	Lee et al.	Oct 2011	B2
8048144	Thistle et al.	Nov 2011	B2
8052636	Moll et al.	Nov 2011	B2
8052700	Dunn	Nov 2011	B2
8062289	Babaev	Nov 2011	B2
8075580	Makower	Dec 2011	B2
8080006	Lafontaine et al.	Dec 2011	B2
8088127	Mayse et al.	Jan 2012	B2
8116883	Williams et al.	Feb 2012	B2
8119183	O'Donoghue et al.	Feb 2012	B2
8120518	Jang et al.	Feb 2012	B2
8123741	Marrouche et al.	Feb 2012	B2
8128617	Bencini et al.	Mar 2012	B2
8131371	Demarals et al.	Mar 2012	B2
8131372	Levin et al.	Mar 2012	B2
8131382	Asada	Mar 2012	B2
8137274	Weng et al.	Mar 2012	B2
8140170	Rezai et al.	Mar 2012	B2
8143316	Ueno	Mar 2012	B2
8145316	Deem et al.	Mar 2012	B2
8145317	Demarais et al.	Mar 2012	B2
8150518	Levin et al.	Apr 2012	B2
8150519	Demarais et al.	Apr 2012	B2
8150520	Demarais et al.	Apr 2012	B2
8152830	Gumm	Apr 2012	B2
8162933	Francischelli et al.	Apr 2012	B2
8168275	Lee et al.	May 2012	B2
8175711	Demarais et al.	May 2012	B2
8187261	Watson	May 2012	B2
8190238	Moll et al.	May 2012	B2
8192053	Owen et al.	Jun 2012	B2
8198611	LaFontaine et al.	Jun 2012	B2
8214056	Hoffer et al.	Jul 2012	B2
8221407	Phan et al.	Jul 2012	B2
8226637	Satake	Jul 2012	B2
8231617	Satake	Jul 2012	B2
8241217	Chiang et al.	Aug 2012	B2
8257724	Cromack et al.	Sep 2012	B2
8257725	Cromack et al.	Sep 2012	B2
8260397	Ruff et al.	Sep 2012	B2
8263104	Ho et al.	Sep 2012	B2
8273023	Razavi	Sep 2012	B2
8277379	Lau et al.	Oct 2012	B2
8287524	Siegel	Oct 2012	B2
8287532	Carroll et al.	Oct 2012	B2
8292881	Brannan et al.	Oct 2012	B2
8293703	Averback et al.	Oct 2012	B2
8295902	Salahieh et al.	Oct 2012	B2
8295912	Gertner	Oct 2012	B2
8308722	Ormsby et al.	Nov 2012	B2
8317776	Ferren et al.	Nov 2012	B2
8317810	Stangenes et al.	Nov 2012	B2
8329179	Ni et al.	Dec 2012	B2
8336705	Okahisa	Dec 2012	B2
8343031	Gertner	Jan 2013	B2
8343145	Brannan	Jan 2013	B2
8347891	Demarais et al.	Jan 2013	B2
8353945	Andreas et al.	Jan 2013	B2
8364237	Stone et al.	Jan 2013	B2
8366615	Razavi	Feb 2013	B2
8382697	Brenneman et al.	Feb 2013	B2
8388680	Starksen et al.	Mar 2013	B2
8396548	Perry et al.	Mar 2013	B2
8398629	Thistle	Mar 2013	B2
8401667	Gustus et al.	Mar 2013	B2
8403881	Ferren et al.	Mar 2013	B2
8406877	Smith et al.	Mar 2013	B2
8409172	Moll et al.	Apr 2013	B2
8409193	Young et al.	Apr 2013	B2
8409195	Young	Apr 2013	B2
8418362	Zerfas et al.	Apr 2013	B2
8452988	Wang	May 2013	B2
8454594	Demarais et al.	Jun 2013	B2
8460358	Andreas et al.	Jun 2013	B2
8465452	Kassab	Jun 2013	B2
8469919	Ingle et al.	Jun 2013	B2
8473067	Hastings et al.	Jun 2013	B2
8480663	Ingle et al.	Jul 2013	B2
8485992	Griffin et al.	Jul 2013	B2
8486060	Kotmel et al.	Jul 2013	B2
8486063	Werneth et al.	Jul 2013	B2
8488591	Miali et al.	Jul 2013	B2
20010007070	Stewart et al.	Jul 2001	A1
20010039419	Francischelli et al.	Nov 2001	A1
20020022864	Mahvi et al.	Feb 2002	A1
20020042639	Murphy-Chutorian et al.	Apr 2002	A1
20020045811	Kittrell et al.	Apr 2002	A1
20020045890	Celliers et al.	Apr 2002	A1
20020062146	Makower et al.	May 2002	A1
20020065542	Lax et al.	May 2002	A1
20020087151	Mody et al.	Jul 2002	A1
20020095197	Lardo et al.	Jul 2002	A1
20020107536	Hussein	Aug 2002	A1
20020147480	Mamayek	Oct 2002	A1
20020169444	Mest et al.	Nov 2002	A1
20020198520	Coen et al.	Dec 2002	A1
20030050635	Truckai et al.	Mar 2003	A1
20030065317	Rudie et al.	Apr 2003	A1
20030092995	Thompson	May 2003	A1
20030139689	Shturman et al.	Jul 2003	A1
20030195501	Sherman et al.	Oct 2003	A1
20030199747	Michlitsch et al.	Oct 2003	A1
20030229340	Sherry et al.	Dec 2003	A1
20030233099	Danaek et al.	Dec 2003	A1
20040010118	Zerhusen et al.	Jan 2004	A1
20040019348	Stevens et al.	Jan 2004	A1
20040024371	Plicchi et al.	Feb 2004	A1
20040043030	Griffiths et al.	Mar 2004	A1
20040064090	Keren et al.	Apr 2004	A1
20040073206	Foley et al.	Apr 2004	A1
20040088002	Boyle et al.	May 2004	A1
20040093055	Bartorelli et al.	May 2004	A1
20040106871	Hunyor et al.	Jun 2004	A1
20040117032	Roth	Jun 2004	A1
20040147915	Hasebe	Jul 2004	A1
20040162555	Farley et al.	Aug 2004	A1
20040167506	Chen	Aug 2004	A1
20040186356	O'Malley et al.	Sep 2004	A1
20040187875	He et al.	Sep 2004	A1
20040193211	Voegele et al.	Sep 2004	A1
20040220556	Cooper et al.	Nov 2004	A1
20040243022	Carney et al.	Dec 2004	A1
20040253304	Gross et al.	Dec 2004	A1
20040267250	Yon et al.	Dec 2004	A1
20050010095	Stewart et al.	Jan 2005	A1
20050015125	Mioduski et al.	Jan 2005	A1
20050080374	Esch et al.	Apr 2005	A1
20050096647	Steinke et al.	May 2005	A1
20050129616	Salcedo et al.	Jun 2005	A1
20050137180	Robinson et al.	Jun 2005	A1
20050143817	Hunter et al.	Jun 2005	A1
20050148842	Wang et al.	Jul 2005	A1
20050149069	Bertolero et al.	Jul 2005	A1
20050149080	Hunter et al.	Jul 2005	A1
20050149158	Hunter et al.	Jul 2005	A1
20050149173	Hunter et al.	Jul 2005	A1
20050149175	Hunter et al.	Jul 2005	A1
20050154277	Tang et al.	Jul 2005	A1
20050154445	Hunter et al.	Jul 2005	A1
20050154453	Hunter et al.	Jul 2005	A1
20050154454	Hunter et al.	Jul 2005	A1
20050165389	Swain et al.	Jul 2005	A1
20050165391	Maguire et al.	Jul 2005	A1
20050165467	Hunter et al.	Jul 2005	A1
20050165488	Hunter et al.	Jul 2005	A1
20050175661	Hunter et al.	Aug 2005	A1
20050175662	Hunter et al.	Aug 2005	A1
20050175663	Hunter et al.	Aug 2005	A1
20050177103	Hunter et al.	Aug 2005	A1
20050177225	Hunter et al.	Aug 2005	A1
20050181004	Hunter et al.	Aug 2005	A1
20050181008	Hunter et al.	Aug 2005	A1
20050181011	Hunter et al.	Aug 2005	A1
20050181977	Hunter et al.	Aug 2005	A1
20050182479	Bonsignore et al.	Aug 2005	A1
20050183728	Hunter et al.	Aug 2005	A1
20050186242	Hunter et al.	Aug 2005	A1
20050186243	Hunter et al.	Aug 2005	A1
20050191331	Hunter et al.	Sep 2005	A1
20050203410	Jenkins	Sep 2005	A1
20050209587	Joye et al.	Sep 2005	A1
20050214205	Salcedo et al.	Sep 2005	A1
20050214207	Salcedo et al.	Sep 2005	A1
20050214208	Salcedo et al.	Sep 2005	A1
20050214209	Salcedo et al.	Sep 2005	A1
20050214210	Salcedo et al.	Sep 2005	A1
20050214268	Cavanagh et al.	Sep 2005	A1
20050228286	Messerly et al.	Oct 2005	A1
20050228415	Gertner	Oct 2005	A1
20050228460	Levin et al.	Oct 2005	A1
20050232921	Rosen et al.	Oct 2005	A1
20050234312	Suzuki et al.	Oct 2005	A1
20050245862	Seward	Nov 2005	A1
20050251116	Steinke et al.	Nov 2005	A1
20050252553	Ginggen	Nov 2005	A1
20050256398	Hastings et al.	Nov 2005	A1
20050267556	Shuros et al.	Dec 2005	A1
20050273149	Tran et al.	Dec 2005	A1
20060004323	Chang et al.	Jan 2006	A1
20060018949	Ammon et al.	Jan 2006	A1
20060024564	Manclaw	Feb 2006	A1
20060025765	Landman et al.	Feb 2006	A1
20060062786	Salcedo et al.	Mar 2006	A1
20060083194	Dhrimaj et al.	Apr 2006	A1
20060085054	Zikorus et al.	Apr 2006	A1
20060089637	Werneth et al.	Apr 2006	A1
20060089638	Carmel et al.	Apr 2006	A1
20060095096	DeBenedictis et al.	May 2006	A1
20060106375	Werneth et al.	May 2006	A1
20060142790	Gertner	Jun 2006	A1
20060147492	Hunter et al.	Jul 2006	A1
20060167106	Zhang et al.	Jul 2006	A1
20060167498	DiLorenzo	Jul 2006	A1
20060171895	Bucay-Couto	Aug 2006	A1
20060182873	Klisch et al.	Aug 2006	A1
20060184221	Stewart et al.	Aug 2006	A1
20060195139	Gertner	Aug 2006	A1
20060206150	Demarais et al.	Sep 2006	A1
20060224153	Fischell et al.	Oct 2006	A1
20060239921	Mangat et al.	Oct 2006	A1
20060240070	Cromack et al.	Oct 2006	A1
20060247266	Yamada et al.	Nov 2006	A1
20060247760	Ganesan et al.	Nov 2006	A1
20060263393	Demopulos et al.	Nov 2006	A1
20060269555	Salcedo et al.	Nov 2006	A1
20060271111	Demarais et al.	Nov 2006	A1
20060287644	Inganas et al.	Dec 2006	A1
20070016184	Cropper et al.	Jan 2007	A1
20070016274	Boveja et al.	Jan 2007	A1
20070027390	Maschke et al.	Feb 2007	A1
20070043077	Mewshaw et al.	Feb 2007	A1
20070043409	Brian et al.	Feb 2007	A1
20070049924	Rahn	Mar 2007	A1
20070066972	Ormsby et al.	Mar 2007	A1
20070067883	Sretavan	Mar 2007	A1
20070073151	Lee	Mar 2007	A1
20070093710	Maschke	Apr 2007	A1
20070100405	Thompson et al.	May 2007	A1
20070106247	Burnett et al.	May 2007	A1
20070112327	Yun et al.	May 2007	A1
20070118107	Francischelli et al.	May 2007	A1
20070129720	Demarais et al.	Jun 2007	A1
20070129760	Demarais et al.	Jun 2007	A1
20070129761	Demarais et al.	Jun 2007	A1
20070135875	Demarais et al.	Jun 2007	A1
20070149963	Matsukuma et al.	Jun 2007	A1
20070162109	Davila et al.	Jul 2007	A1
20070173805	Weinberg et al.	Jul 2007	A1
20070179496	Swoyer et al.	Aug 2007	A1
20070203480	Mody et al.	Aug 2007	A1
20070207186	Scanlon et al.	Sep 2007	A1
20070208134	Hunter et al.	Sep 2007	A1
20070208210	Gelfand et al.	Sep 2007	A1
20070208256	Marilla	Sep 2007	A1
20070208301	Evard et al.	Sep 2007	A1
20070219576	Cangialosi	Sep 2007	A1
20070225781	Saadat et al.	Sep 2007	A1
20070233170	Gertner	Oct 2007	A1
20070239062	Chopra et al.	Oct 2007	A1
20070248639	Demopulos et al.	Oct 2007	A1
20070249703	Mewshaw et al.	Oct 2007	A1
20070254833	Hunter et al.	Nov 2007	A1
20070265687	Deem et al.	Nov 2007	A1
20070278103	Hoerr et al.	Dec 2007	A1
20070282302	Wachsman et al.	Dec 2007	A1
20070292411	Salcedo et al.	Dec 2007	A1
20070293782	Marino	Dec 2007	A1
20070299043	Hunter et al.	Dec 2007	A1
20080004673	Rossing et al.	Jan 2008	A1
20080009927	Vilims	Jan 2008	A1
20080015501	Gertner	Jan 2008	A1
20080021408	Jacobsen et al.	Jan 2008	A1
20080033049	Mewshaw	Feb 2008	A1
20080039746	Hissong et al.	Feb 2008	A1
20080039830	Munger et al.	Feb 2008	A1
20080051454	Wang	Feb 2008	A1
20080064957	Spence	Mar 2008	A1
20080071269	Hilario et al.	Mar 2008	A1
20080071306	Gertner	Mar 2008	A1
20080082109	Moll et al.	Apr 2008	A1
20080086072	Bonutti et al.	Apr 2008	A1
20080091193	Kauphusman et al.	Apr 2008	A1
20080097251	Babaev	Apr 2008	A1
20080097426	Root et al.	Apr 2008	A1
20080108867	Zhou	May 2008	A1
20080119879	Brenneman et al.	May 2008	A1
20080125772	Stone et al.	May 2008	A1
20080132450	Lee et al.	Jun 2008	A1
20080140002	Ramzipoor et al.	Jun 2008	A1
20080147002	Gertner	Jun 2008	A1
20080161662	Golijanin et al.	Jul 2008	A1
20080161717	Gertner	Jul 2008	A1
20080161801	Steinke et al.	Jul 2008	A1
20080171974	Lafontaine et al.	Jul 2008	A1
20080172035	Starksen et al.	Jul 2008	A1
20080172104	Kieval et al.	Jul 2008	A1
20080188912	Stone et al.	Aug 2008	A1
20080188913	Stone et al.	Aug 2008	A1
20080208162	Joshi	Aug 2008	A1
20080208169	Boyle et al.	Aug 2008	A1
20080213331	Gelfand et al.	Sep 2008	A1
20080215117	Gross	Sep 2008	A1
20080221448	Khuri-Yakub et al.	Sep 2008	A1
20080234790	Bayer et al.	Sep 2008	A1
20080243091	Humphreys et al.	Oct 2008	A1
20080245371	Gruber	Oct 2008	A1
20080249525	Lee et al.	Oct 2008	A1
20080249547	Dunn	Oct 2008	A1
20080255550	Bell	Oct 2008	A1
20080255642	Zarins et al.	Oct 2008	A1
20080262489	Steinke	Oct 2008	A1
20080275484	Gertner	Nov 2008	A1
20080281312	Werneth et al.	Nov 2008	A1
20080281347	Gertner	Nov 2008	A1
20080287918	Rosenman et al.	Nov 2008	A1
20080294037	Richter	Nov 2008	A1
20080300618	Gertner	Dec 2008	A1
20080312644	Fourkas et al.	Dec 2008	A1
20080312673	Viswanathan et al.	Dec 2008	A1
20080317818	Griffith et al.	Dec 2008	A1
20090018486	Goren et al.	Jan 2009	A1
20090018609	DiLorenzo	Jan 2009	A1
20090024194	Arcot-Krishnamurthy et al.	Jan 2009	A1
20090030312	Hadjicostis	Jan 2009	A1
20090036948	Levin et al.	Feb 2009	A1
20090043372	Northrop et al.	Feb 2009	A1
20090054082	Kim et al.	Feb 2009	A1
20090062873	Wu et al.	Mar 2009	A1
20090069671	Anderson	Mar 2009	A1
20090076409	Wu et al.	Mar 2009	A1
20090088735	Abboud et al.	Apr 2009	A1
20090105631	Kieval	Apr 2009	A1
20090112202	Young	Apr 2009	A1
20090118620	Tgavalekos et al.	May 2009	A1
20090118726	Auth et al.	May 2009	A1
20090125099	Weber et al.	May 2009	A1
20090131798	Minar	May 2009	A1
20090143640	Saadat et al.	Jun 2009	A1
20090156988	Ferren et al.	Jun 2009	A1
20090157057	Ferren et al.	Jun 2009	A1
20090157161	Desai et al.	Jun 2009	A1
20090171333	Hon	Jul 2009	A1
20090192558	Whitehurst et al.	Jul 2009	A1
20090198223	Thilwind et al.	Aug 2009	A1
20090203962	Miller et al.	Aug 2009	A1
20090203993	Mangat et al.	Aug 2009	A1
20090204170	Hastings et al.	Aug 2009	A1
20090210953	Moyer et al.	Aug 2009	A1
20090216317	Cromack et al.	Aug 2009	A1
20090221955	Babaev	Sep 2009	A1
20090226429	Salcedo et al.	Sep 2009	A1
20090240249	Chan et al.	Sep 2009	A1
20090247933	Maor et al.	Oct 2009	A1
20090247966	Gunn et al.	Oct 2009	A1
20090248012	Maor et al.	Oct 2009	A1
20090253974	Rahme	Oct 2009	A1
20090264755	Chen et al.	Oct 2009	A1
20090270850	Zhou et al.	Oct 2009	A1
20090281533	Ingle et al.	Nov 2009	A1
20090287137	Crowley	Nov 2009	A1
20090318749	Stolen et al.	Dec 2009	A1
20100009267	Chase et al.	Jan 2010	A1
20100030061	Canfield et al.	Feb 2010	A1
20100048983	Ball et al.	Feb 2010	A1
20100049099	Thapliyal et al.	Feb 2010	A1
20100049186	Ingle et al.	Feb 2010	A1
20100049188	Nelson et al.	Feb 2010	A1
20100049191	Habib et al.	Feb 2010	A1
20100049283	Johnson	Feb 2010	A1
20100069837	Rassat et al.	Mar 2010	A1
20100076299	Gustus et al.	Mar 2010	A1
20100076425	Carroux	Mar 2010	A1
20100087782	Ghaffari et al.	Apr 2010	A1
20100106005	Karczmar et al.	Apr 2010	A1
20100114244	Manda et al.	May 2010	A1
20100130836	Malchano et al.	May 2010	A1
20100137860	Demarais et al.	Jun 2010	A1
20100137952	Demarais	Jun 2010	A1
20100160903	Krespi	Jun 2010	A1
20100160906	Jarrard	Jun 2010	A1
20100168624	Sliwa	Jul 2010	A1
20100168731	Wu et al.	Jul 2010	A1
20100168739	Wu et al.	Jul 2010	A1
20100174282	Demarais et al.	Jul 2010	A1
20100191112	Demarais et al.	Jul 2010	A1
20100191232	Boveda	Jul 2010	A1
20100217162	Hissong et al.	Aug 2010	A1
20100222786	Kassab	Sep 2010	A1
20100222851	Deem et al.	Sep 2010	A1
20100222854	Demarais et al.	Sep 2010	A1
20100228122	Keenan et al.	Sep 2010	A1
20100249604	Hastings et al.	Sep 2010	A1
20100249773	Clark et al.	Sep 2010	A1
20100256616	Katoh et al.	Oct 2010	A1
20100268217	Habib	Oct 2010	A1
20100268307	Demarais et al.	Oct 2010	A1
20100284927	Lu et al.	Nov 2010	A1
20100286684	Hata et al.	Nov 2010	A1
20100298821	Garbagnati	Nov 2010	A1
20100305036	Barnes et al.	Dec 2010	A1
20100312141	Keast et al.	Dec 2010	A1
20100324472	Wulfman	Dec 2010	A1
20110009750	Taylor et al.	Jan 2011	A1
20110021976	Li et al.	Jan 2011	A1
20110034832	Cioanta et al.	Feb 2011	A1
20110040324	McCarthy et al.	Feb 2011	A1
20110044942	Puri et al.	Feb 2011	A1
20110060324	Wu et al.	Mar 2011	A1
20110071400	Hastings et al.	Mar 2011	A1
20110071401	Hastings et al.	Mar 2011	A1
20110077498	McDaniel	Mar 2011	A1
20110092781	Gertner	Apr 2011	A1
20110092880	Gertner	Apr 2011	A1
20110104061	Seward	May 2011	A1
20110112400	Emery et al.	May 2011	A1
20110118600	Gertner	May 2011	A1
20110118726	De La Rama et al.	May 2011	A1
20110130708	Perry et al.	Jun 2011	A1
20110137155	Weber et al.	Jun 2011	A1
20110144479	Hastings et al.	Jun 2011	A1
20110146673	Keast et al.	Jun 2011	A1
20110166499	Demarais et al.	Jul 2011	A1
20110178570	Demarais	Jul 2011	A1
20110200171	Beetel et al.	Aug 2011	A1
20110202098	Demarais et al.	Aug 2011	A1
20110207758	Sobotka et al.	Aug 2011	A1
20110208096	Demarais et al.	Aug 2011	A1
20110257523	Hastings et al.	Oct 2011	A1
20110257564	Demarais et al.	Oct 2011	A1
20110257622	Salahieh et al.	Oct 2011	A1
20110257641	Hastings et al.	Oct 2011	A1
20110257642	Griggs, III	Oct 2011	A1
20110263921	Vrba et al.	Oct 2011	A1
20110264011	Wu et al.	Oct 2011	A1
20110264075	Leung et al.	Oct 2011	A1
20110264086	Ingle	Oct 2011	A1
20110264116	Kocur et al.	Oct 2011	A1
20110270238	Rizq et al.	Nov 2011	A1
20110306851	Wang	Dec 2011	A1
20110319809	Smith	Dec 2011	A1
20120029496	Smith	Feb 2012	A1
20120029500	Jenson	Feb 2012	A1
20120029505	Jenson	Feb 2012	A1
20120029509	Smith	Feb 2012	A1
20120029510	Haverkost	Feb 2012	A1
20120029511	Smith et al.	Feb 2012	A1
20120029512	Willard et al.	Feb 2012	A1
20120029513	Smith et al.	Feb 2012	A1
20120059241	Hastings et al.	Mar 2012	A1
20120059286	Hastings et al.	Mar 2012	A1
20120065506	Smith	Mar 2012	A1
20120065554	Pikus	Mar 2012	A1
20120095461	Herscher et al.	Apr 2012	A1
20120101413	Beetel et al.	Apr 2012	A1
20120101490	Smith	Apr 2012	A1
20120101538	Ballakur et al.	Apr 2012	A1
20120109021	Hastings et al.	May 2012	A1
20120116382	Ku et al.	May 2012	A1
20120116383	Mauch et al.	May 2012	A1
20120116392	Willard	May 2012	A1
20120116438	Salahieh et al.	May 2012	A1
20120116486	Naga et al.	May 2012	A1
20120123243	Hastings	May 2012	A1
20120123258	Willard	May 2012	A1
20120123261	Jenson et al.	May 2012	A1
20120123303	Sogard et al.	May 2012	A1
20120123406	Edmunds et al.	May 2012	A1
20120130289	Demarais et al.	May 2012	A1
20120130345	Levin et al.	May 2012	A1
20120130359	Turovskiy	May 2012	A1
20120130360	Buckley et al.	May 2012	A1
20120130362	Hastings et al.	May 2012	A1
20120130368	Jenson	May 2012	A1
20120130458	Ryba et al.	May 2012	A1
20120136344	Buckley et al.	May 2012	A1
20120136349	Hastings	May 2012	A1
20120136350	Goshgarian et al.	May 2012	A1
20120136417	Buckley et al.	May 2012	A1
20120136418	Buckley et al.	May 2012	A1
20120143181	Demarais et al.	Jun 2012	A1
20120143293	Mauch et al.	Jun 2012	A1
20120143294	Clark et al.	Jun 2012	A1
20120150267	Buckley et al.	Jun 2012	A1
20120157986	Stone et al.	Jun 2012	A1
20120157987	Steinke et al.	Jun 2012	A1
20120157988	Stone et al.	Jun 2012	A1
20120157989	Stone et al.	Jun 2012	A1
20120157992	Smith et al.	Jun 2012	A1
20120157993	Jenson et al.	Jun 2012	A1
20120158101	Stone et al.	Jun 2012	A1
20120158104	Huynh et al.	Jun 2012	A1
20120172837	Demarais et al.	Jul 2012	A1
20120172870	Jenson et al.	Jul 2012	A1
20120184952	Jenson et al.	Jul 2012	A1
20120197198	Demarais et al.	Aug 2012	A1
20120197252	Deem et al.	Aug 2012	A1
20120232409	Stahmann et al.	Sep 2012	A1
20120265066	Crow et al.	Oct 2012	A1
20120265198	Crow et al.	Oct 2012	A1
20120296329	Ng	Nov 2012	A1
20130012844	Demarais et al.	Jan 2013	A1
20130012866	Deem et al.	Jan 2013	A1
20130012867	Demarais et al.	Jan 2013	A1
20130013024	Levin et al.	Jan 2013	A1
20130023865	Steinke et al.	Jan 2013	A1
20130035681	Subramanaim et al.	Feb 2013	A1
20130066316	Steinke et al.	Mar 2013	A1
20130085489	Fain et al.	Apr 2013	A1
20130090563	Weber	Apr 2013	A1
20130090578	Smith et al.	Apr 2013	A1
20130090647	Smith	Apr 2013	A1
20130090649	Smith et al.	Apr 2013	A1
20130090650	Jenson et al.	Apr 2013	A1
20130090651	Smith	Apr 2013	A1
20130090652	Jenson	Apr 2013	A1
20130096550	Hill	Apr 2013	A1
20130096553	Hill et al.	Apr 2013	A1
20130096554	Groff et al.	Apr 2013	A1
20130096604	Hanson et al.	Apr 2013	A1
20130110106	Richardson	May 2013	A1
20130116687	Willard	May 2013	A1
20130158536	Bloom	Jun 2013	A1
20130165764	Scheuermann et al.	Jun 2013	A1
20130165844	Shuros et al.	Jun 2013	A1
20130165916	Mathur et al.	Jun 2013	A1
20130165917	Mathur et al.	Jun 2013	A1
20130165920	Weber et al.	Jun 2013	A1
20130165923	Mathur et al.	Jun 2013	A1
20130165924	Mathur et al.	Jun 2013	A1
20130165925	Mathur et al.	Jun 2013	A1
20130165926	Mathur et al.	Jun 2013	A1
20130165990	Mathur et al.	Jun 2013	A1
20130172815	Perry et al.	Jul 2013	A1
20130172872	Subramaniam et al.	Jul 2013	A1
20130172877	Subramaniam et al.	Jul 2013	A1
20130172878	Smith	Jul 2013	A1
20130172879	Sutermeister	Jul 2013	A1
20130172880	Willard	Jul 2013	A1
20130172881	Hill et al.	Jul 2013	A1
20140074083	Horn et al.	Mar 2014	A1

Foreign Referenced Citations (44)

Number	Date	Country
10038737	Feb 2002	DE
1053720	Nov 2000	EP
1180004	Feb 2002	EP
1335677	Aug 2003	EP
1874211	Jan 2008	EP
1906853	Apr 2008	EP
1961394	Aug 2008	EP
1620156	Jul 2009	EP
2076193	Jul 2009	EP
2091455	Aug 2009	EP
2197533	Jun 2010	EP
2208506	Jul 2010	EP
1579889	Aug 2010	EP
2092957	Jan 2011	EP
2349044	Aug 2011	EP
2027882	Oct 2011	EP
2378956	Oct 2011	EP
2037840	Dec 2011	EP
2204134	Apr 2012	EP
2320821	Oct 2012	EP
2456301	Jul 2009	GB
9858588	Dec 1998	WO
9900060	Jan 1999	WO
9935986	Jul 1999	WO
0047118	Aug 2000	WO
0066021	Nov 2000	WO
0195820	Dec 2001	WO
03026525	Apr 2003	WO
2004100813	Nov 2004	WO
2004110258	Dec 2004	WO
2005041810	May 2005	WO
2006105121	Oct 2006	WO
2008014465	Jan 2008	WO
2009121017	Oct 2009	WO
2010067360	Jun 2010	WO
2010102310	Sep 2010	WO
2010132703	Nov 2010	WO
2011005901	Jan 2011	WO
2011053757	May 2011	WO
2011053772	May 2011	WO
2011091069	Jul 2011	WO
2011130534	Oct 2011	WO
2012019156	Feb 2012	WO
2013049601	Apr 2013	WO

Non-Patent Literature Citations (69)

Entry
US 8,398,630, 03/2013, Demarais et al. (withdrawn)
Van Den Berg, “Light echoes image the human body,” OLE, Oct. 2001, p. 35-37.
“IntraLuminal: Products,” IntraLuminal Therapeutics, Inc., 2003, p. 1-9.
“Laser Catheter to Aid Coronary Surgery,” TechTalk: MIT, Jan. 9, 1991, p. 1-4.
“Optical Coherence Tomography: LightLab Imaging Starts US Cardiology Clinical Investigations,” LightLab Imaging Technology, 2002.
“Optical Coherence Tomography: LightLab Sees Bright Prospects for Cardiac Application of OCT Technology,” LightLab Imaging Technology, 2001, vol. 27, No. 35.
“Products—Functional Measurement,” VOLCANO Functional Measurement Products US, Mar. 24, 2003, p. 1-2.
Brown et al., “Radiofrequency capacitive heaters: the effect of coupling medium resistivity on power absorption along a mouse leg,” Physics in Medicine and Biology, 1993, p. 1-12, vol. 38.
Carrington, “Future of CVI: It's all about plaque: Identification of vulnerable lesions, not ‘rusty pipes,’ could become cornerstone of preventive cardiology,” Diagnostic Imaging, 2001, p. 1-8.
Chen et al., “Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo,” EuroIntervention, 2013, p. 1-8.
Cimino, “Preventing plaque attack,” Mass High Tech, 2001, p. 1-2.
Dahm et al., “Relation of Degree of Laser Debulking of In-Stent Restenosis as a Predictor of Restenosis Rate,” The American Journal of Cardiology, 2002, p. 68-70, vol. 90.
De Korte et al., “Characterization of Plaque Components With Intravascular Ultrasound Elastography in Human Femoral and Coronary Arteries In Vitro,” Circulation, Aug. 8, 2000, p. 617-623.
Durney et al., “Radiofrequency Radiation Dosimetry Handbook,” Oct. 1986, p. 1-2, Fourth Edition.
Durney et al., “Radiofrequency Radiation Dosimetry Handbook: Contents,” Oct. 1986, p. 1-5, Fourth Edition.
Fournier-Desseux et al., “Assessment of 1-lead and 2-lead electrode patterns in electrical impedance endotomography,” Physiological Measurement, 2005, p. 337-349. Vo. 26, Institute of Physics Publishing.
Fram et al., “Feasibility of Radiofrequency Powered, Thermal Balloon Ablation of Atrioventricular Bypass Tracts via the Coronary Sinus: In Vivo Canine Studies,” PACE, Aug. 1995, p. 1518-1530, vol. 18.
Fram et al., “Low Pressure Radiofrequency Balloon Angioplasty: Evaluation in Porcine Peripheral Arteries,” JACC, 1993, p. 1512-1521, vol. 21, No. 6, American College of Cardiology.
Fujimori et al., “Significant Prevention of In-Stent Restenosis by Evans Blue in Patients with Acute Myocardial Infarction,” American Heart Association, 2002.
Fujita et al., “Sarpogrelate, An Antagonist of 5-HT(2A) Receptor, Treatment Reduces Restenosis After Coronary Stenting,” American Heart Association, 2002.
Gabriel, “Appendix A: Experimental Data,” 1999, p. 1-21.
Gabriel, “Appendix C: Modeling the frequency dependence of the dielectric properties to a 4 dispersions spectrum,” p. 1-49, Nov. 6, 1997.
Gregory et al., “Liquid Core Light Guide for Laser Angioplasty,” The Journal of Quantum Electronics, Dec. 1990, p. 2289-2296, vol. 26, No. 12.
Kaplan et al., “Healing after Arterial Dilatation with Radiofrequency Thermal and Nonthermal Balloon Angioplasty Sytems,” Journal of Investigative Surgery, 1993, p. 33-52, vol. 6.
Kolata, “New Studies Question Value of Opening Arteries,” The New York Times, Mar. 21, 2004, p. 1-5.
Konings et al., “Development of an Intravascular Impedance Catheter for Detection of Fatty Lesions in Arteries,” IEEE Transactions on Medical Imaging, Aug. 1997, p. 439-446, vol. 16, No. 4.
Kurtz et al., “Lamellar Refractive Surgery with Scanned Intrastromal Picosecond and Femtosecond Laser Pulses in Animal Eyes,” Journal of Refractive Surgery, Sep./Oct. 1998, p. 541-548.
Lee et al., “Thermal Compression and Molding of Atherosclerotic Vascular Tissue With Use of Radiofrequency Energy: Implications for Radiofrequency Balloon Angioplasty,” JACC, 1989, p. 1167-1175, vol. 13, No. 5, American College of Cardiology.
Lima et al., “Efficacy and Safety of Oral Sirolimus to Treat and Prevent In-Stent Restenosis: A Pilot Study Results,” American Heart Association, 2002, p. 2929.
Lima et al., “Systemic Immunosuppression Inhibits In-Stent Coronary Intimal Proliferation in Renal Transplant Patients,” American Heart Association, 2002, p. 2928.
Morice et al., “A Randomized Comparison of a Sirolimus-Eluting Stent With a Standard Stent for Coronary Revascularization,” The New England Journal of Medicine, Jun. 6, 2012, p. 1773-1780, vol. 346, No. 23.
Muller-Leisse et al., “Effectiveness and Safety of Ultrasonic Atherosclerotic Plaque Ablation: In Vitro Investigation,” CardioVascular and Interventional Radiology, 1993, p. 303-307, vol. 16.
Nair et al., “Regularized Autoregressive Analysis of Intravascular Ultrasound Backscatter: Improvement in Spatial Accuracy of Tissue Maps,” IEEE Transactions on Ultrasonics, Apr. 2004, p. 420-431, vol. 51, No. 4.
Popma et al., “Percutaneous Coronary and Valvular Intervention,” Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th edition, p. 1364-1405, 2005.
Resar et al., “Endoluminal Sealing of Vascular Wall Disruptions With Radiofrequency-Heated Balloon Angioplasty,” Catheterization and Cardiovascular Diagnosis, 1993, p. 161-167, vol. 29.
Romer et al., “Histopathology of Human Coronary Atherosclerosis by Quantifying Its Chemical Composition With Raman Spectroscopy,” Circulation, 1998, p. 878-885, vol. 97.
Schauerte et al., “Catheter Ablation of Cardiac Autonomic Nerves for Prevention of Vagal Atrial Fibrillation,” Circulation, 2000, p. 2774-2780, vol. 102.
Scheller et al., “Intracoronary Paclitaxel Added to Contrast Media Inhibits In-Stent Restenosis of Porcine Coronary Arteries,” American Heart Association, 2002, p. 2227.
Scheller et al., “Potential solutions to the current problem: coated balloon,” EuroIntervention, 2008, p. C63-C66, vol. 4 (Supplement C).
Shaffer, “Scientific basis of laser energy,” Clinics in Sports Medicine, 2002, p. 585-598, vol. 21.
Shmatukha et al., “MRI temperature mapping during thermal balloon angioplasty,” Physics in Medicine and Biology, 2006, p. N163-N171, vol. 51.
Slager et al., “Vaporization of Atherosclerotic Plaques by Spark Erosion,” J Am Coll Cardiol, 1985, p. 21-25.
Stiles et al., “Simulated Characterization of Atherosclerotic Lesions in the Coronary Arteries by Measurement of Bioimpedance,” IEEE Transactions on Biomedical Engineering, Jul. 2003, p. 916-921, vol. 50, No. 7.
Suselbeck et al., “In vivo intravascular electric impedance spectroscopy using a new catheter with integrated microelectrodes,” Basic Res Cardiol, 2005, p. 28-34, vol. 100.
Suselbeck et al., “Intravascular electric impedance spectroscopy of atherosclerotic lesions using a new impedance catheter system,” Basic Res Cardiol, 2005, p. 446-452, vol. 100.
Tepe et al., “Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg,” The New England Journal of Medicine, 2008, p. 689-699, vol. 358.
“Optical Coherence Tomography: Advantages of OCT,” LightLab Imaging Technology, printed Sep. 3, 2003.
“Optical Coherence Tomography: Image Gallery Cardiovascular Procedures,” LightLab Imaging Technology, printed Sep. 3, 2003.
“Optical Coherence Tomography: What is OCT?,” LightLab Imaging Technology, printed Sep. 3, 2003.
“Optical Coherence Tomography: Why Use OCT?,” LightLab Imaging Technology, printed Sep. 3, 2003.
Pieper et al. “Design and implementation of a new computerized system for intraoperative cardiac mapping”, J. Appl. Physiol. 71(4): 1529-1539, 1991.
CardioVascular Technologies Inc., “Heated Balloon Device Technology,” 11 pages, 2008.
Strategic Business Development, Inc., “Thermal and Disruptive Angioplasty: A Physician's Guide,” 8 pages, 1990.
Zhang et al., “Non-contact Radio-Frequency Ablation for Obtaining Deeper Lesions,” IEEE Transaction on Biomedical Engineering, vol. 50, No. 2, 6 pages, Feb. 2003.
Lazebnik et al., “Tissue Strain Analytics Virtual Touch Tissue Imaging and Qualification,” Siemens Whitepaper, Oct. 2008, 7 pages.
Han et al., “Third-Generation Cryosurgery for Primary and Recurrent Prostate Caner,” BJU International, vol. 93, pp. 14-18, 2004.
Zhou et al., “Mechanism Research of Cryoanalgesia,” Forefront Publishing Group, 1995.
Florete, “Cryoblative Procedure for Back Pain,” Jacksonville Medicine, Oct. 1998, 10 pages.
Stevenson, “Irrigated RF Ablation: Power Titration and Fluid Management for Optimal Safety Efficacy,” 2005, 4 pages.
Giliatt et al., “The Cause of Nerve Damage in Acute Compression,” Trans Am Neurol Assoc, 1974: 99; 71-4.
Omura et al., “A Mild Acute Compression Induces Neurapraxia in Rat Sciatic Nerve,” The International Journal of Neuroscience, vol. 114 (12), pp. 1561-1572, Dec. 2004.
Baun, “Interaction with Soft Tissue,” Principles of General & Vascular Sonography, Chapter 2, pp. 23-24, Before Mar. 2012.
Blue Cross Blue Shield Medical Policy, “Surgery Section—MRI-Guided Focused Ultrasound (MRgFUS) for the Treatment of Uterine Fibroids and Other Tumors,” 2005, 5 pages.
Gentry et al., “Combines 3D Intracardiac Echo and Ultrasound Ablation,” Medical Imaging 2003: Ultrasonic and Signal Processing, vol. 5035, 2003, pp. 166-173.
Lafon et al., “Optmizing the Shape of Ultrasound Transducers for Interstitial Thermal Ablations,” MEd Phys. Mar. 2002; 29(3): 290-7 (abstract only).
G. Ter Haar, “Ultrasound Focal Beam Surgery,” Ultrasound in Med. & Biol., 1995, vol. 21, No. 9, pp. 1089-1100.
Seip et al., “Transurethral High Intensity Focused Ultrasound: Catheter Based Prototypes and Experimental Results,” IEEE Ultrasonics Symposium Proceeding, 2000, 4 pages.
Toytman et al., “Tissue Dissection with Ultrafast Laser Using Extended and Multiple Foci,” SPIE Proceeding, Optical Interactions with Tissues and Cells XXI, vol. 7562, 2010, 10 pages.
Zhou et al., “Non-Thermal Ablation of Rabbit Liver VX2 Tumore by Pulsed High Intensity Focused Ultrasound Contrast Agent: Pathological Characteristics,” World Journal of Gastroenterology, vol. 14(43), Nov. 21, 2008, pp. 6743-6747.

Related Publications (1)

	Number	Date	Country
	20140378966 A1	Dec 2014	US

Provisional Applications (1)

	Number	Date	Country
	61838086	Jun 2013	US

Renal denervation balloon catheter with ride along electrode support

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

CPC

Field of Search

US

CPC

International Classifications

Term Extension

Abstract